TMF-11822142  CONFIDENTIAL  
GlaxoSmithKline group of companies   212602  
1 
 TITLE PAGE  
Protocol Title: B-Fine: An open label, single arm study to mechanistic ally interrogate 
the therapeutic effect of [COMPANY_004]3228836 in patients with Chronic Hepatitis B via 
intrahepatic immunophenotypi[INVESTIGATOR_102976] : 212602 /Amendment 01  
Compound Number  [COMPANY_004]3228836  
 
Brief Title: A mechanistic study of [COMPANY_004]3228836 with fine needle aspi[INVESTIGATOR_1516] ( FNA ) in 
Participants with Chronic Hepatitis B  
Study Phase:  PHASE IIA  
Acronym : B-Fine  
Sponsor Name [CONTACT_29560]:  
GlaxoSmithKline Research & Development Limited  
[ADDRESS_113984]  
Middlesex, TW8 9GS  
[LOCATION_006] 
Regulatory Agen cy Identifying Number(s):   
IND: [ADDRESS_113985]: 2020 -002000 -39 
Approval Date:  15-MAR -2021 
Copyright 202 1 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copying or use of this information is prohibited.  
 
 

TMF-11822142  CONFIDENTIAL  
 212602  
2 
 SPONSOR SIGNATORY:  
Protocol Title: B-Fine: An open label, single arm study to mechanistically interrogate 
the therapeutic effect of [COMPANY_004]3228836 in patients with Chronic Hepatitis B via 
intrahepatic immunophenotypi[INVESTIGATOR_102976] : 212602/Amendment [ADDRESS_113986] Information   
Can be found in the Study Reference Manual  
 
TMF-11822142  CONFIDENTIAL  
 212602  
3 
 PROTOCOL  AMENDMENT SUMMARY  OF CHANGES  TABLE  
DOCUMENT HISTORY  
Document  Date  DNG Number  
Amendment 01 15-MAR -2021  TMF-11822142  
Original Protocol  29-MAY -2020  2020N434303_00  
 
Amendment 01 15-MAR -2021  
This amendment is considered to be substantial  based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
Overall Rationale for the Amendment:   
 
 
  
Other key changes include :  
• a description of the risk of Covid -[ADDRESS_113987] of the Medicines & Healthcare products  Regulatory Agency  (MHRA ). 
• an update to the time to maximum  alanine aminotransferase  (ALT ) analysis method . 
• additional guidance and clarity for Investigators has been a dded . 
• corrections to visit windows and visit numbering in the  schedule of activities  (SoA). 
In addition, minor t ypographical errors and inconsistencies have been corrected and 
minor editorial changes have been made.  
Section # and Name  [CONTACT_9353] 1.1 Synopsis: 
Key Objectives and 
Endpoints  HBe antibody (anti -HBeAg) levels have 
been re-classified as a categorical 
variable (previously a continuous  
variable)  This corrects an error in the original 
protocol.  
 The analysis method for the time to 
maximum ALT has been updated from 
Kaplan -Meier to Turnbull  As visit spacing gets longer over time, 
interval censored method is more 
appropriate.  
Section 1.3: Schedule 
of Activities  The Day 11 visit window was been 
updated from 3 days to 1 day  Updated to avoid potential overlap of 
the Day 8 and Day 11 visits  
 Collection of PBMC samples for 
immunophenotypi[INVESTIGATOR_102977] 
“Baseline,  Day 8 (Week 2) , Day 15 
(Week 3) , Day 29 (Week 5),  Day 85 
(Week 13) , Day 162  (Week 24),  Day 
246 (Week 36) and Early Withdrawal ” to 
“Baseline, Day 29 (Week 5), Day 246 
(Week 36) and Early Withdrawal. ” Amended  to reduce sampling timepoints 
due to increased blood volume required 
for PBMC  analysis.  
CCI
TMF-11822142  CONFIDENTIAL  
 212602  
4 
 Section # and Name  [CONTACT_103096] h as been updated from 
brief physical exam to symptoms 
directed exam  Updated to reflect risk reduction 
practices in limiting physical contact [CONTACT_103041] -19 and to align with 
assessments covered by [CONTACT_103042].  
 Clarification has been added that  PK 
sample should be collected pre -dose.  This corrects an error in the original 
protocol.  
 Guidance has been added that a  fine 
needle aspi[INVESTIGATOR_1516]  (FNA) sample not to 
be collected if the participant has 
already withdrawn from treatment  Updated to reduce bur den on 
participants who no longer wish to 
continue study treatment.  
 A urine or serum pregnancy test has 
been added as an optional assessment 
at Day 1  Added for instances where the 
Screening serum  human  chorionic 
gonadotrophin  (hCG) pregnancy test 
was >[ADDRESS_113988] been rem oved from the 
SoA at all timepoints other than Week -1 
(Baseline)  This corrects an error in the original 
protocol.  
Section 2.3.1: Risk 
Assessment  Additional text added on risk with 
COVID -19 infection  Provide description of risk of COVID -19 
infection in hepatitis B population  
Section 2.3.3 Overall 
Benefit: Risk 
Conclusion  Additional text added on benefit/risk with 
COVID -19 infection  Include COVID -19 risk in the overall 
benefit:risk assessment  
Section 3: Objectives 
and Endpoints  HBe antibody (anti -HBeAg)  levels have 
been re -classified as a categorical 
variable (previously a continuous 
variable)  This corrects an error in the original 
protocol.  
 The analysis method for the time to 
maximum ALT has been updated from 
Kaplan -Meier to Turnbull  As visit spacing gets longer over time, 
interval censored method is more 
appropriate. Turnbull method chosen, 
and this is consistent with Study 209348 
(B-Together).  
 Immunophenotypi[INVESTIGATOR_102978].  
Section 5.[ADDRESS_113989] for 
clarification following protocol review by 
[CONTACT_84272] . 
Section 6.3: Measures 
to Minimize Bias: 
Randomization and 
Blinding  Additional text added on bias mitigation  Updated to include reference to the 
blinding plan  
Section 6.8.2  
Prohibited Medications 
and Non -Drug 
Therapi[INVESTIGATOR_102979] -coagulation therapi[INVESTIGATOR_102980] -drug 
therapi[INVESTIGATOR_102981]-11822142  CONFIDENTIAL  
 212602  
5 
 Section # and Name  [CONTACT_9353] 7.1.1: Liver 
Chemistry Monitoring 
and Stoppi[INVESTIGATOR_102982] ‘Bold’  
• Any clinically significant  
deterioration from the baseline in the 
liver parameters must be confirmed 
by [CONTACT_103043], total bilirubin, direct 
bilirubin, and INR (if available).  
• Cases such as Gilbert syndrome, 
where baseline bilirubin values a re 
high, should be discussed with the 
medical monitor, to assess if it is a 
case of  drug -induced liver injury  
(DILI) or the participant may 
continue with dosing.  To clarify and identify  instances where 
advice from the medical monitor should 
be sought  
Section 7.1.3: 
Haematological 
Stoppi[INVESTIGATOR_102983].  
Section 7.1.5: Study 
Intervention Restart or 
Rechallenge after 
Stoppi[INVESTIGATOR_102984] ‘Bold ’ as follows: 
Institutional Review Boards 
(IRB)/Independent Ethics Committees 
(IEC) approval of study intervention 
restart has been obtained (if required).  This corrects an error in the original 
protocol.  
Section 8.2.1: Physical 
Examinations  Description of  post-baseline brief 
physical examination updated to 
symptoms directed examination  Updated to reflect risk reduction 
practices in limiting physical contact [CONTACT_103041] -19 and to align with 
assessments covered by [CONTACT_103042].  
Section 8.2.3: Vit al 
Signs  Requirement for vital sign measurement 
in a semi -supi[INVESTIGATOR_102985].  Updated as not required.  
Section 9.4.4: 
Secondary Endpoint(s)  HBe antibody (anti -HBeAg) changed 
from a continuous to a categorical 
variable  This is to represent the data which have 
received since the start of the study.  
 The analysis method for the time to 
maximum ALT has been updated from 
Kaplan -Meier to Turnbull  As visit spacing gets longer over time, 
interval censored method is more 
appropriate.  
Section 9.6 : 
Independent Data 
Monitoring Com mittee 
(IDMC)  Additional  detail  added regarding the 
timing of IDMC safety reviews  Updated to describe the planned safety 
reviews  
Section 10.2: Appendix 
2 Clinical Laboratory 
Tests  Additional text regarding processing of 
PBMC samples  Updated to allow for local laboratory 
processing of PBMC samples.  
 Bilirubin SAE reporting requirement s 
updated  from 2xULN to 2xULN  To correct an error in the definition .  
Section 10. 6: Appendix 
6: Liver Safety: 
Required Actions and 
Follow -up 
Assessments and 
Study Intervention 
Restart Guidelines  Added text in ‘ Bold ’ as follows: 
Institutional Review Boards 
(IRB)/Independent Ethics Committees 
(IEC) approval of study intervention 
restart has been obtained (if required).  
 This corrects an error in the original 
protocol.  
TMF-11822142  CONFIDENTIAL   
  212602  
6 
 TABLE OF CONTENTS  
PAGE  
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE ................................ ..... 3 
1. PROTOCOL SUMMARY  ................................ ................................ ..........................  9 
1.1. Synopsis  ................................ ................................ ................................ ....... 9 
1.2. Schema  ................................ ................................ ................................ ...... 13 
1.3. Schedule of Activities (SoA)  ................................ ................................ ........  13 
2. INTRODUCTION  ................................ ................................ ................................ .... 19 
2.1. Study Rationale  ................................ ................................ ..........................  19 
2.2. Background  ................................ ................................ ................................  19 
2.3. Benefit/Risk Assessment  ................................ ................................ ............  21 
2.3.1.  Risk Assessment  ................................ ................................ .........  21 
2.3.2.  Benefit Assessment  ................................ ................................ ..... 24 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ..................  24 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ...........  25 
4. STUDY DESIGN  ................................ ................................ ................................ .... 28 
4.1. Overall Desig n ................................ ................................ ............................  28 
4.2. Scientific Rationale for Study Design  ................................ ..........................  28 
4.2.1.  Participant Input into Design  ................................ ........................  32 
4.3. Justification for Dose  ................................ ................................ ..................  32 
4.4. End of Study Definition  ................................ ................................ ...............  34 
5. STUDY POPULATION  ................................ ................................ ...........................  34 
5.1. Inclusion Criteria  ................................ ................................ .........................  35 
5.2. Exclusion Criteria  ................................ ................................ ........................  36 
5.3. Lifestyle Considerations  ................................ ................................ ..............  39 
5.3.1.  Alcohol and Tobacco  ................................ ................................ ... 39 
5.3.2.  Activity  ................................ ................................ .........................  39 
5.4. Screen Failures ................................ ................................ ...........................  39 
5.5. Criteria for Temporarily Delaying Administration of Study 
Intervention  ................................ ................................ ................................ . 39 
6. STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY  ..............................  40 
6.1. Study Intervention(s) Administered  ................................ .............................  40 
6.2. Preparation/Handling/Storage/Accountability  ................................ ..............  40 
6.3. Measures to Minimize Bias: Randomization and Blinding  ...........................  41 
6.4. Study Intervention Compliance  ................................ ................................ ... 41 
6.5. Dose Modification  ................................ ................................ .......................  41 
6.6. Continued Access to Study Intervention after the End of the Study  ............  41 
6.7. Treatment of Overdose  ................................ ................................ ...............  41 
6.8. Concomitant Therapy ................................ ................................ ..................  42 
6.8.1.  Nucleos(t)ide Treatment during and after the End of the 
Study  ................................ ................................ ...........................  42 
6.8.2.  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]  .........................  42 
7. DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..... 43 
7.1. Discontinuation of Study Intervention  ................................ ..........................  43 
TMF-11822142  CONFIDENTIAL   
  212602  
7 
 7.1.1.  Liver Chemistry Monitoring and Stoppi[INVESTIGATOR_2121]  ........................  43 
7.1.2.  Drug Induced Vascular Inflammation and Complement 
Stoppi[INVESTIGATOR_2121]  ................................ ................................ ..........  46 
7.1.3.  Haematological Stoppi[INVESTIGATOR_007] C riteria  ................................ .................  47 
7.1.4.  Drug Induced Kidney Injury (Renal) Stoppi[INVESTIGATOR_2121]  ..................  48 
7.1.5.  Study Intervention Restart or Rechallenge after Stoppi[INVESTIGATOR_102986]  ................................ ................................ ..................  49 
7.2. Participant Discontinuation/Withdrawal from the Study  ...............................  [ADDRESS_113990] to Follow Up  ................................ ................................ ........................  51 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  51 
8.1. Efficacy Assessments  ................................ ................................ .................  52 
8.2. Safety Assessments  ................................ ................................ ...................  52 
8.2.2.  Injection Site Reactions  ................................ ...............................  52 
8.2.5.  Clinical Safety Laboratory Assessments  ................................ ...... 53 
8.2.6.  Adverse Events and Serious Adverse Events  ..............................  54 
[IP_ADDRESS].  Time Period and Frequency for Collecting AE 
and SAE Information  ................................ ..................  54 
[IP_ADDRESS].  Method of Detecting AEs and SAE s ...........................  54 
[IP_ADDRESS].  Follow -up of AEs and SAEs  ................................ ........  54 
[IP_ADDRESS].  Regulatory Reporting Requirements for SAEs  ............  [ADDRESS_113991]  ................................ ..............  56 
[IP_ADDRESS].  ALT Increases  ................................ ............................  56 
[IP_ADDRESS].  Vascular Inflammation and Complement 
Activation  ................................ ................................ .... 56 
[IP_ADDRESS].  Thrombocytopenia  ................................ ......................  56 
[IP_ADDRESS].  Renal Injury  ................................ ................................  56 
[IP_ADDRESS].  Injection Site Reactions  ................................ ..............  57 
8.3. Pharmacokinetics  ................................ ................................ .......................  57 
8.4. Biomark ers ................................ ................................ ................................ . 57 
8.5. Resistance Monitoring  ................................ ................................ ................  58 
8.6. Medical Resource Utilization and Health Economics  ................................ .. 59 
9. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  59 
9.1. Statistical Hypotheses ................................ ................................ .................  59 
9.2. Sample Size Determination  ................................ ................................ ........  59 
9.3. Analysis Sets  ................................ ................................ ..............................  62 
9.4. Statistical Analyses  ................................ ................................ .....................  62 
9.4.1.  General Considerati ons ................................ ...............................  62 
9.4.2.  Primary Endpoint(s)  ................................ ................................ ..... 62 
9.4.3.  Primary Analyses  ................................ ................................ .........  63 
9.4.4.  Secondary Endpoint(s)  ................................ ................................  64 
9.4.5.  Safety Endpoints  ................................ ................................ ..........  66 
9.4.6.  Exploratory Endpoint(s)  ................................ ...............................  66 
9.5. Interim Analysis  ................................ ................................ ..........................  67 
9.6. Indepen dent Data Monitoring Committee (IDMC)  ................................ ....... 67 
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ...............................  68 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ............................  68 
TMF-11822142  CONFIDENTIAL   
  212602  
8 
 10.1.1.  Regulatory and Ethical Considerations  ................................ ........  68 
10.1.2.  Financial Disclosure  ................................ ................................ ..... 68 
10.1.3.  Informed Consent Process  ................................ ..........................  69 
10.1.4.  Data Protection  ................................ ................................ ............  69 
10.1.5.  Committees Structure  ................................ ................................ .. 70 
10.1.6.  Dissemination of Clinical Study Data  ................................ ...........  70 
10.1.7.  Data Quality Assurance  ................................ ...............................  71 
10.1.8.  Source Documents  ................................ ................................ ...... 72 
10.1.9.  Study and Site Start and Closure  ................................ .................  72 
10.1.10.  Publication Policy  ................................ ................................ .........  73 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ .........................  74 
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ....... 77 
10.3.1.  Definition of AE  ................................ ................................ ............  77 
10.3.2.  Definition of SAE  ................................ ................................ ..........  78 
10.3.3.  Definition of Cardiovascular Events  ................................ .............  79 
10.3.4.  Recording and Follow -Up of AE and SAE  ................................ .... 80 
10.3.5.  Reporting of SAE to [COMPANY_004]  ................................ .............................  82 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ ....... 83 
10.4.1.  Definitions:  ................................ ................................ ...................  83 
10.4.2.  Contraception Guidance:  ................................ .............................  84 
10.4.3.  Collection of Pregnancy Information:  ................................ ...........  85 
10.5.  Appendix 5: Genetics  ................................ ................................ ..................  86 
10.6.  Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Restart Guidelines  ............................  87 
10.7.  Appendix 7: Abbreviations and Trademarks  ................................ ................  90 
11. REFERENCES  ................................ ................................ ................................ ....... 93 
 
TMF-11822142  CONFIDENTIAL   
  212602  
9 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Title:  
B-Fine: An open label, single arm study to mechanistically interrogate the therapeutic 
effect of [COMPANY_004]3228836 in patients with Chronic Hepatitis B via intrahepatic 
immunophenotypi[INVESTIGATOR_102987]:  
B-Fine is an exploratory study of the therapeutic mechanism of [COMPANY_004]3228836 in  
participants with chronic hepatitis B ( CHB ) on stable nucleos(t)ide therapy .  The study will 
investigate the virologic and immunologic correlates of HBsAg loss observed in 
participants when treated for 12 weeks with 300 mg [COMPANY_004]3228836.  Repeat fine needle 
aspi[INVESTIGATOR_102988] -resident immune cells to 
investigate any immunomodulatory properties of [COMPANY_004]3228836 and to study the biology of 
underlying treatment -associated liver flares.  Longitudinal analyses of bloo d-borne 
inflammatory signatures and virological assessments of CHB infection will be performed 
in parallel.  
Key Objectives and Endpoints:  
Objectives  Estimands/Endpoints  
Primary  
Efficacy : To assess the effect of 
12 weeks of [COMPANY_004]3228836 on 
serum hepatitis B  virus surface 
antigen ( HBsAg ) levels in 
participants with CHB  The Primary Estimand  supporting the primary objective of the study is 
defined as:  
• Population: Participants with CHB  who receive at least one dose of 
investigational product ( IP) 
• Treatment: 300  mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Variable: Achieving serum HBsAg level <lower limit of quantitation 
(LLOQ ) at any time point up to and including Week 12  without the 
use of pegylated ( PEG )-interferon or other immunomodulato r 
therapi[INVESTIGATOR_014]  
• Population -level summary: Percent of participants that achieve 
serum HBsAg level <LLOQ  
• Intercurrent events: Discontinuation of, interruption of, and 
adherence to IP will be ignored (treatment policy).  
 
The primary estimand is the percentage of participants with CHB receiving 
300 mg [COMPANY_004]3228836 for 12 weeks  (with at least one dose of IP)  who 
achieve serum HBsAg level <LLOQ at any time point up to and including 
Week 12  without the use of PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_014] , regardless  of completing IP, interruptions in IP or adherence to IP . 
TMF-11822142  CONFIDENTIAL   
  212602  
10 
 Objectives  Estimands/Endpoints  
Secondary  
Efficacy: To assess sustainability 
of serum HBsAg loss by 
[CONTACT_23983]3228836 for up to 24 weeks 
off-treatment.  The Estimand supporting the objective is defined as:  
• Population:   Participants with CHB  who receive at least one dose of 
IP 
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Variable s:   
o Sustained HBsAg Response (HBsAg <LLOQ) for 24 weeks 
after the planned end of [COMPANY_004]3228836 treatment  
▪ HBsAg from Week 13 to Week 36 will be used to assess 
sustained HBsAg response after the planned end of  
[COMPANY_004]3228836 treatment  without the use of PEG -interferon or 
other immunomodulator therapi[INVESTIGATOR_014] .  
o Sustained HBsAg Response (HBsAg <LLOQ) for 24 weeks 
after the actual end of [COMPANY_004]3228836 treatment  
▪ HBsAg for 24 weeks after end of actual treatment will also 
be used to assess sustained HBsAg response after the 
actual end of [COMPANY_004]3228836 treatment  without the use of 
PEG -interferon or other immunomodulator therapi[INVESTIGATOR_014] . 
• Intercurrent event s: Discontinuation of, interruption of, and 
adherence to IP will be ignored (treatment policy) .  
The group of estimands supporting this objective in participants with CHB 
receiving 300 mg [COMPANY_004]3228836 for 12 weeks (with  at least one dose of IP ) is 
the percentage of participants for each variable regardless of completing IP, 
interruptions in IP or adherence to IP,  without the use of PEG -interferon or 
other immunomodulator therapi[INVESTIGATOR_014] . 
Efficacy: To assess sustainability 
of serum HBsAg and HBV DNA 
loss by [CONTACT_23983]3228836 for up to 24 
weeks off treatment.  The Estimand supporting the objective is defined as:  
• Population: Participants with CHB  who receive at least one dose of 
IP 
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Variables : 
o Sustained  Virologic Response (HBsAg <LLOQ and HBV DNA 
<LLOQ) for 24 weeks after the planned end of [COMPANY_004]3228836 
treatment  without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014] . 
▪ HBsAg and HBV DNA from Week 13 to Week 36 will be used 
to assess sustained virologic response after the planned end 
of [COMPANY_004]  [COMPANY_004]3228836 treatment.  
o Sustained  Virologic Response (HBsAg <LLOQ and HBV DNA 
<LLOQ) for 24 weeks after the actual end of [COMPANY_004]3228836 
treatment  without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014]  
▪ HBsAg and HBV DNA for 24 weeks after end of actual 
treatment will be used to assess sustained virologic response 
after the actual end of [COMPANY_004]3228836 treatment.  
• Intercurrent events: Discontinuation of, interruption of, and 
adherence to IP will be ignored (treatment policy).  
 
The group of estimands supporting this objective in partic ipants with CHB 
receiving 300 mg [COMPANY_004]3228836 for 12 weeks (with  at least one dose of IP ) is 
the percentage of participants for each variable regardless of completing IP, 
interruptions in IP or adherence to IP,  without the use of PEG -interferon or 
other immu nomodulator therapi[INVESTIGATOR_014] . 
TMF-11822142  CONFIDENTIAL   
  212602  
11 
 Objectives  Estimands/Endpoints  
Efficacy : To assess the effect of 
[ADDRESS_113992] of 
12 weeks [COMPANY_004]3228836 on biomarkers and virus -specific antibody responses 
are defined as follows:   
• Population: Participants with CHB  who receive at least one dose of 
IP 
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Intercurrent events: Discontinuation of, interruption of, adherence to 
IP will be ignored (treatment policy). PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_102989] . 
1) Categorical Variables:  
• Achieving :  
o HBsAg  <LLOQ over time  
o HBV DNA <LLOQ over time  
o HBsAg  and HBV DNA <LLOQ over time  
• Categorical  changes from baseline in HBsAg (e.g. <0.5, 0.5, 1, 
1.5, 3 log 10 IU/mL) over time.  
• ALT>3X ULN at over time  
• HBe antibody (anti -HBeAg) levels over time  
Population summary: percentage of pa rticipants in each category.  
2) Continuous Variables:  
• Actual values and change from baseline over time for HBsAg and 
HBV DNA  
• HBs antibody (anti -HBsAg) levels over time  
• Area under the curve (AUC) for ALT on treatment (12 weeks), 
during follow up (24 weeks), and on treatment + follow up (36 
weeks).  
Population summary: mean values  and/or mean changes from baseline  for 
each variable  
3) Time to Event Variable  
• Time to Maximum ALT (ALT must be greater than 3xULN) during 
36 weeks of treatment + follow up  
Population summary: Turnbull  estimate for median Time to Maximum ALT 
(>3xULN)  
The group of estimands supporting this objective in participants with CHB 
receiving 300  mg [COMPANY_004]3228836 for 12 weeks  (with at least one dose of IP)  are 
the population summary for each variable  in the absence of  PEG -interferon or 
other immunomodulator therapi[INVESTIGATOR_014] , regardless of completing IP, interruptions 
in IP, or adherence to IP .  
Overall Design:  
This study is a Phase IIa, multi -centre open  label exploratory study of the therapeutic 
mechanism of [COMPANY_004]3228836 in participants with HBeAg -negative CHB on stable 
nucleos(t)ide therapy using repeat fine needle aspi[INVESTIGATOR_102990].  
The study consists of a single  treatment arm  
1. 300 mg [COMPANY_004]3228836 for 12 weeks (loading schedule on Day 4 and Day 11).  
Participants will continue to receive their stable nucleos(t)ide therapy.  
TMF-[ADDRESS_113993] -treatment follow -up 
period of 24 weeks.  
 
Brief Summary:  
The purpose of this study is to determine the therapeutic mechanism of [COMPANY_004]3228836 in 
participants with CHB. Study details include:  
Study Duration : 37 weeks  (45 weeks if include screening  and flexible visit windows)  
Treatment Du ration : 12 weeks  
Visit Frequency : Twice a week for the first 2 weeks, once a week through Week 14, once 
at Week 16, and once every 4 weeks thereafter  
Study Hypothesis : [COMPANY_004]3228836 treatment will result in phenotypic changes in 
intrahepatic immunity associat ed with loss of HBsAg and treatment -emergent changes in 
ALT  
Health Measurement/Observation : HBsAg <LLOQ  
Number of Participants:  
The study will enrol approximately 20 participants, but no more than 24.  
Note : "Enrolled" means a participant's, or their legall y acceptable representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
and eligibility process. Potential participants who are screened for the purpose of 
determining eligibility for the study, but do not p articipate in the study, are not 
considered enrolled, unless otherwise specified by [CONTACT_760].  
Intervention Groups and Duration:  
The total duration of the study, including screening, treatment and post -treatment follow -
up, is not expected to exceed 45 weeks.  
o 45-day screening window. Eligible participants who fall out of the 45 -day 
window may be re -screened at the discretion of the Investigator/site  
o Up to 1 week of pre -treatment assessments (including baseline FNA)  
o [ADDRESS_113994] treatment follow -up (+ up to 10 days)  
There are no plans for dose adjustments.  Individual dose adjustments for safety are 
outlined in the monitoring/stoppi[INVESTIGATOR_3418].  
Data Monitoring/ Other Committee:  Yes 
TMF-11822142  CONFIDENTIAL   
  212602  
13 
 1.2. Schema  
 
 
An optional 6th FNA may be included between Weeks 6 and 36  following discussion between investigator and medical 
monitor.  
1.3. Schedule of Activities (SoA)  
In selected countries/sites, participants will have the option to use a centralised home 
nursing provider . Only selected visits will have the option to be performed as a home 
visit.  Home visits may  include drug administration, blood draws, participant assessments 
and data collection. The full specifications of the home nursing services will be outlined 
in the study reference manual ( SRM ). 
Table 1 Screening  
ASSESSMENTS  (45 Day window)   
Informed Consent  X 
Inclusion and exclusion criteria  X 
Demography  X 
Medical history (includes substance usage) and current medical conditions  X 
Medication history and concomitant medication review  X 
Full physical exam including height and weight  X 
Vital signs  X 
12-lead ECG  X 
LABORATORY ASSESSMENTS  
Serum hCG pregnancy test (women of child -bearing potential)  X 
FSH/Estradiol (to confirm status of women of non -child-bearing potential)1 X 
Hematology/Chemistry/Urinalysis  X 
Urine ACR  X 
PT, INR, aPTT  X 
HIV, hepatitis D, and hepatitis C screen  X 
Hepatitis B profile (HBsAg, HBV DNA, HBeAg)  X 
Alpha -fetoprotein  X 
APRI/Fibrosure/Fibrotest X 
ANCA2 X 
Complement C3, C4, C5a, hsCRP, MCP -1, complement Bb, Ang -II X 
1. As appropriate to confirm menopause.  
2. With MPO -ANCA, PR3 -ANCA if results are positive or border -line positive  

TMF-11822142  CONFIDENTIAL   
  212602  
14 
 Table 2 On-Treatment Day -7 to Day 50  
Assessments  Day -7 to Day -1 D1 D4 D8 D11 D15 D22 D29 D36 D43 D50 
 Week -1 (Baseline)  W1 W1 W2 W2 W3 W4 W5 W6 W7 W8 
Window   1 day   3 days  
Study treatment dosing1  X X X X X X X X X X 
Safety Assessments   
AE/SAE review  X X X X X X X X X X X 
Concomitant medication review  X X X X X X X X X X X 
Symptoms directed  exam  X X      X    
Vital signs X X X X X X X X X X X 
Injection site reactions  X X X X X X X X X X 
Laboratory   
Pregnancy test (women of child bearing potential)2 X       X    
Hematology3[includes platelet count and WBC] X X  X  X X X X X X 
PT, INR, aPTT  X X    X  X    
Chemistry  X X  X  X X X X X X 
Urinalysis  X X  X  X X X X X X 
Urine ACR X X    X  X  X  
HBsAg and HBV DNA  X X  X  X X X X X X 
Anti-HBsAg  X       X    
Anti-HBeAg  X       X    
HBV RNA, HBcrAg, and sequencing (HBV genotype /phenotype , HBV DNA and/or RNA)  X     X X X   X 
Complement C3, Complement C4, hs -CRP, MCP -1 X X    X  X  X  
Complement C5a, Complement factor Bb  X X    X  X  X  
ANCA, Ang II  X X      X    
PK4  X  X  X X X X X X 
Fine needle aspi[INVESTIGATOR_102991]5 X     X6  X6    
PBMC Collection for immunophenotypi[INVESTIGATOR_007]  X       X    
Soluble Protein  X   X  X X X   X 
PAXGene RNA for expression analysis in whole blood  X   X  X  X    
Genetics  X           
Archived samples [serum; plasma]  X   X  X  X  X  
TMF-11822142  CONFIDENTIAL   
  212602  
15 
 Assessments  Day -7 to Day -1 D1 D4 D8 D11 D15 D22 D29 D36 D43 D50 
 Week -1 (Baseline)  W1 W1 W2 W2 W3 W4 W5 W6 W7 W8 
Optional Assessments   
Urine or serum pregnancy test7  X          
Optional: fine needle aspi[INVESTIGATOR_102991]8         X X X 
Optional: PBMC Collection for immunophenotypi[INVESTIGATOR_007]9         X X X 
Optional: Soluble Protein9         X X X 
Optional: PAXGene RNA for expression analysis in whole blood9         X X X 
 
1. Dosing to occur only after the completion of all assessments to determine dosing is safe to proceed  
2. Women of childbearing potential ( WOCBP ) must have both:  
a. A confirmed menstrual period prior to the first dose of study intervention; additional evaluation (e.g., amenorrhea in athlet es, birth control) should also be considered  
b. AND a negative highly sensitive pregnancy test [urine or serum] before the first dose of study treatment  
3. Hematology - platelet count to be analyzed at local laboratory  prior to dose ; hematology samples to be collected for central laboratory asse ssments in parallel  
4. PK samples are to be taken pre -dose  
5. FNA will only be collected if the investigator deems it appropriate  
6. Within [ADDRESS_113995] was >[ADDRESS_113996] assessments.  
 
TMF-11822142  CONFIDENTIAL   
  212602  
16 
 Table 3 On-Treatment Day 57 to Day 78  
Assessments  D57 D64 D71 D78 
 W9 W10 W11 W12 
Window   3 days  
Study treatment dosing  X X X X 
Safety Assessments   
AE/SAE review  X X X X 
Concomitant medication review  X X X X 
Symptoms directed  exam  X    
Vital signs X X X X 
Injection site reactions X X X X 
Laboratory   
Pregnancy test (women of child bearing potential)  X    
Hematology1 [includes platelet count and WBC with differential] X X X X 
PT, INR, aPTT  X    
Chemistry  X X X X 
Urinalysis  X X X X 
Urine ACR X  X  
HBsAg and HBV DNA  X X X X 
Anti-HBsAg  X    
Anti-HBeAg  X    
HBV RNA, HBcrAg, and Sequencing (HBV genotype /phenotype ; HBV DNA and/or RNA)     X 
Complement C3, Complement C4, hs-CRP, MCP -1 X  X  
Complement C5a, Complement factor Bb  X  X  
ANCA, Ang II  X    
PK2 X X X X 
Soluble Protein     X 
Archived samples [serum; plasma]  X  X  
Optional Assessments   
Optional: fine needle aspi[INVESTIGATOR_102991]3 X X X X 
Optional: PBMC Collection for immunophenotypi[INVESTIGATOR_007]3 X X X X 
Optional: Soluble Protein4 X X X X 
Optional: PAXGene RNA for expression analysis in whole blood4 X X X X 
TMF-11822142  CONFIDENTIAL   
  212602  
17 
 1. Hematology - platelet count to be analyzed at local laboratory  prior to dose ; hematology samples to be collected for central laboratory assessments in parallel  
2. PK samples are to be taken pre -dose. 
3. An optional additional FNA may be collected anytime between Week 6 and Week 36 following discussion between investigator and medical monitor based on unexpected changes 
in HBsAg or ALT. Only 1 additional FNA may be collected for each participant.  
4. Only to be collected if the optional FNA is collected at this visit and has not already been collected as part of the standar d assessments.  
 
Table 4 Off-Treatment Follow -Up Day 85 to Day 246 
Assessments   Day 85  Day 92  Day 106  Day 134  Day 162  Day 190 Day 218 Day 246 Early 
Termination  
  W 13  W 14  W 16  W 20  W 24  W 28  W 32  W 36  NA 
Window   3 days   10 days  
Safety Assessments   
AE/SAE review  X X X X X X X X X 
Concomitant medication review  X X X X X X X X X 
Symptoms directed  exam  X X  X X X X X X 
Vital signs X X X X X X X X X 
Laboratory   
Pregnancy test (women of child 
bearing potential)  X  X X X X X X X 
Hematology1 (includes platelet count, 
and WBC with differential) X X X X X X X X X 
PT, INR, aPTT  X X X X X X X X X 
Chemistry  X X X X X X X X X 
Urinalysis  X X X X X X X X X 
Urine ACR X X X X X X X X X 
HBsAg and HBV DNA  X X X X X X X X X 
Anti-HBsAg  X X X X X X X X X 
Anti-HBeAg  X X X X X X X X X 
HBV RNA, HBcrAg , and Sequencing 
(HBV genotype /phenotype ; HBV DNA 
and/or RNA)  X  X  X X X X X 
TMF-11822142  CONFIDENTIAL   
  212602  
18 
 Assessments   Day 85  Day 92  Day 106  Day 134  Day 162  Day 190 Day 218 Day 246 Early 
Termination  
  W 13  W 14  W 16  W 20  W 24  W 28  W 32  W 36  NA 
Complement C3, Complement C4, hs -
CRP, MCP -1  X X X X X X X X 
Complement C5a, Complement factor 
Bb  X X X X X X X X 
ANCA, Ang II X  X X X X X X X 
PK X X X X X X X X X 
Fine Needle Aspi[INVESTIGATOR_102992]2 X       X X 
PBMC Collection for 
immunophenotypi[INVESTIGATOR_007]         X X 
PAXGene RNA for expression analysis 
in whole blood  X    X   X X 
Soluble Protein  X  X  X  X X X 
APRI/Fibrosure         X X 
Archived Samples [serum; plasma]  X X X X X X X X X 
Optional Assessments   
Optional: fine needle aspi[INVESTIGATOR_102991]3  X X X X X X   
Optional: PBMC Collection for 
immunophenotypi[INVESTIGATOR_007]4  X X X X X X   
Optional: Soluble Protein4  X X X X X X   
Optional: PAXGene RNA for 
expression analysis in whole blood4  X X X X X X   
1. Hematology - platelet count analyzed at local laboratory is optional  during the off -treatment period; hematology samples to be collected for central laboratory assessments  
2. FNA will only be collected if the investigator deems it appropriate  
3. An optional additional FNA may be collected anytime between Week 6 and Week 36 following discussion between investigator and medical monitor based on unexpected 
changes in HBsAg or ALT. Only 1  additional FNA may be collected for each participant.  
4. Only to be collected if the optional FNA is collected at this visit and has not already been collected as part of the standar d assessments.  
 
TMF-11822142  CONFIDENTIAL   
  212602  
19 
 2. INTRODUCTION  
2.1. Study Rationale  
B-Fine is an exploratory study of the therapeutic mechanism of [COMPANY_004]3228836 in 
participants with HBeAg -negative CHB on stable nucleos(t)ide therapy .  The study will 
investigate the virologic and immunologic correlates of HBsAg loss observed in 
participants when treated for 12 weeks with [COMPANY_004]3228836.  Repeat fine needle aspi[INVESTIGATOR_102993] -resident immun e cells to investigate 
any immunomodulatory properties of [COMPANY_004]3228836 and to study the biology of underlying 
treatment -associated liver flares.  Longitudinal analyses of blood -borne inflammatory 
signatures and virological assessments of CHB infection will b e performed in parallel.  
2.2. Background  
HBV infection, especially chronic infection, is a significant worldwide medical problem.  
Globally, in 2015, an estimated 257 million people were living with chronic Hepatitis B, 
with only 9% of patients with Hepatitis B  being treated. Viral hepatitis led to 1.34 million 
deaths and of these deaths, 66% were the results of complications of CHB infection [ WHO , 
2015].  
The goal of therapy for CHB is to improve quality of life and survival by [CONTACT_103044], decompensated liver disease, end -stage liver 
disease, hepatocellular carcinoma (HCC), or death. This goal can be achieved if HBV 
replication is suppressed in a s ustained manner thereby [CONTACT_103045] [ Liaw , 2004; Feld, 2009]. In both 
HBeAg -positive and HBeAg -negative CHB, the ultimate treatment endpoint is loss of 
detectable serum hepatitis B surface antigen (HBsAg) and serum HBV DNA [ Lok, 2009; 
EASL , 2012]. Loss of HBsAg is preceded by a robust immunological response to HBV 
infection resulting in sustained suppression of serum HBV deoxyribonucleic acid (DNA) 
and disease resolution.  
First-line therapy for CHB is treatment with a nucleoside or nucleotide (nucleos(t)ide) 
analogue (NA). While these antiviral agents are effective in suppressing HBV replication 
in both HBeAg -positive and HBeAg -negative CHB, patients frequently relapse after 
treatmen t is discontinued, particularly if HBsAg loss was not achieved. Treatment with a 
pegylated interferon (PEG -interferon), of which 2 are available, is also approved for CHB 
[Lok, 2009; EASL , 2012] for a defined treatment duration (usually up to 48 weeks). 
Because of their frequent and sometimes severe side effects and high c ost versus a small 
gain in treatment response, PEG -interferons are less frequently used than NAs. 
Unfortunately, with both the NAs and PEG -interferon, HBsAg loss and the subsequent 
development of antibodies to HBsAg is rarely achieved. Rates of HBsAg loss following 12 
months of treatment with either a NA or PEG -interferon generally range from 0 to 3% in 
most studies [ Lok, 2009; EASL , 2012]. Loss of HBeAg occurs more frequently following 
treatment with either the NAs or PEG -interferon, approximately 15 to 30% after [ADDRESS_113997] 
TMF-11822142  CONFIDENTIAL   
  212602  
20 
 patients on treatment fail to achieve a sustained off -treatment virological response and 
require extended and often life -long therapy to suppress HBV DNA.  
It has been proposed that the contin ued production of viral antigens by [CONTACT_103046] 
[Vanlandschoot , 2003]. In vitro studies with human peripheral blood mononuclear cells 
(PBMCs) have shown HBsAg impairs the functioning of dendritic cells and inhibits the 
activation of monocytes [ Vanlandschoot , 2002; Op den Brouw , 2009]. Further, data 
suggest the production of vast exc ess of HBsAg (so called non-infectious  “sub-viral 
particles”) likely functions as a decoy for host antibody responses. Most chronically 
infected patients produce antibody to HBsAg, but these can only be detected as immune 
complexes due to the vast excess o f circulating antigen [ Maruyama , 1993]. HBeAg is also 
thought to have a role in immune response evasion through down regulation of the innate 
immune sys tem [ Milich , 1998; Wu, 2009; Walsh , 2012]. As noted above, since loss of 
HBsAg expression is rarely achieved while loss of  HBeAg expression occurs in a higher 
proportion of the patient population, HBsAg appears to be the main antagonist of immune 
clearance.  
Should the viral antigens be instrumental in preventing clearance of persistent infection by 
[CONTACT_27639], reducin g the expression of these antigens, especially HBsAg, would 
be expected to permit reconstitution of an immune response against HBV [ Boni , 2007; 
Boni, 2012; Bertoletti , 2013]. Support for this hypothesis is the observation that 
spontaneous seroconversion and resolution of chronic infection is most likely in patients 
that have lower serum HBsAg levels [ Chen , 2012; Höner Zu Siederdissen , 2014].  
Similarly, during treatment with NAs, patients with low HBsAg levels are more likely to 
lose HBsAg and seroconvert to anti -HBs antibody positive than patients with high HBsAg 
levels [ Wursthorn , 2010; Jaroszewicz , 2011; Boni, 2012; Höner Zu Siederdissen , 2014].  
A study to examine whether inhibition of HBsAg production for a finite duration would 
lead to sustained suppression of HBV has not been possible up to the present due to the 
lack of spec ific inhibitors of HBsAg.  
[COMPANY_004]3228836, an antisense oligonucleotide, was designed to inhibit the synthesis of 
HBsAg without having a direct effect on covalently closed circular DNA (cccDNA) or 
integrated HBV DNA. [COMPANY_004]3228836 directly targets all HBV mRNAs vi a Ribonuclease 
H (RNase H) mediated degradation, resulting in the reduction of viral proteins including 
HBsAg. [COMPANY_004]3228836 treatment permits examination of whether reduction of HBsAg 
allows resumption of a host immune response against HBV and infected cells  and can 
suppress serum HBsAg to <LLOQ.   [COMPANY_004]3228836 has been designed and selected to 
minimize risk of proinflammatory response associated as a class effect  by [CONTACT_103047]  [Henry , 2008] .  However, it is 
expected that [COMPANY_004]3228836  may trigger marginal immune activation in the local 
environment of the liver, which may not be readily detectable in periphery.  In turn, the 
intrinsic immunostimulatory activity of [COMPANY_004]3228836  may contribute to the efficacy in 
addition to direct pharmacodynamic response of HBsAg reduction  [Yuen , 2019] .   
Recently, a functional cure of CHB infection has been endorsed as the endpoint for new 
HBV therapi[INVESTIGATOR_014]  [Kim, 2018] . Functional cure of CHB infection is defined as sustained 
TMF-11822142  CONFIDENTIAL   
  212602  
21 
 suppression of serum HBsAg to <LLOQ (with or without anti -HBsAg seroconversion,) 
and undetectable HBV DNA in serum, after completion of a finite course of treatment 
[Lok, 2017].  
Functional cure occurs in only a very small percentage of patients on NA therapy alone 
(approx. 3% per annum), meaning that patients frequently relapse once they are taken off 
treatment [ Lok, 2017].  The high rate of relapse in these patients is hypothesised to be due 
to their inability to raise an effective immune response to the virus in the presence of high 
circulating levels of HBsAg, which continues to be produced by [CONTACT_103048], even 
in the absence of ongoing viral replication.  
2.3. Benefit/Risk Assessment  
More detailed information about the identified and potential benefits and risks and 
expected adverse events of [COMPANY_004]3228836 may be found in the Investigator’s Brochure.  
2.3.1.  Risk Assessment  
Risks are summarized in Table 5.  Additional withdrawal/stoppi[INVESTIGATOR_102994], drug induced vascular inflammation (DIVI) , hematology, renal function, and 
PK are discussed in Section 7. 
 
TMF-11822142  CONFIDENTIAL   
  212602  
22 
 Table 5 Summary of Potential Risks of Clinical Significance  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Investigational Product (IP) [e.g., [COMPANY_004]3228836]  
Nonclinical Risks :  
Drug Induced Vascular Inflammation and Complement 
Activation  Inflammatory and immune changes are recognized as a 
class effect of antisense oligonucleotides (ASOs). 
Vasculitis and/or perivascular inflammation has been 
described in monkey  studies with many if not most ASOs . 
 
This effect has not been observed in clinical studies with 
[COMPANY_004]3228836 to date . Laboratory Evaluations : Inclusion of biomarker panels 
to look for inflammatory and immune activation that would 
be expected to accompany va scular inflammation  
 
Stoppi[INVESTIGATOR_2121]:  Proposed Monitoring Schedule and 
Stoppi[INVESTIGATOR_102995] (see Section 7.1.2 ) 
 
Clinical Risks : 
Drug induced liver injury / ALT Flares  The liver is a site of accumulation of antisense 
oligonucleotides. Liver findings in nonclinical studies of 
[COMPANY_004]3228836 were generally limited to mild hepatic 
enzyme elevations associated with hepatic vacuolation 
without concomitant histologic evidence of degeneration 
in mice, consistent with findings noted with other 2' -
methoxyethyl (MOE) ASOs. Review of the available 
clinical data indicates liver enzymes are increased on 
treatment with AS Os in a low percentage of patients 
compared to placebo.  
ALT elevations (defined as ALT 2X ULN) associated 
with HBsAg reductions were observed in 8 out of 18 
treatment -naïve participants in the ISIS 505358 -CS3 
study [150 mg [COMPANY_004]3228836, N=6; 300 mg [COMPANY_004]3228836, 
N=12].  Among the 8 participants with ALT flares, 6 
achieved >1 log HBsAg reduction, another 2 had >0.5 log 
HBsAg reduction.  Laboratory Evaluati ons: hepatic enzyme monitoring as 
presented in Table 7 
 
Stoppi[INVESTIGATOR_2121]: ALT flares are expected in the study 
population. Monitoring and stoppi[INVESTIGATOR_102996] 7.1.1  
TMF-11822142  CONFIDENTIAL   
  212602  
23 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Thrombocytopenia leading to clinically significant bleeding 
events  Two types of thrombocytopenia have been described for 
the 2'-MOE ASOs [ Chi, 2017; Crooke , 2017].  One type is 
a rapid onset, unpredictable thrombocytopenia.  The other 
more common type is characterised by a gradual decline 
in platelets leading to mild to severe thrombocytopenia 
and can be asymptomatic or associated with mild to 
severe bleeding.   In monkeys given [COMPANY_004]322883 6, there 
were incidences of both types in a 39 -week study.  
Thrombocytopenia was not reported in the clinical studies 
with [COMPANY_004]3228836 (ISIS 505358 -CS1 and ISIS 505358 -
CS3)  Laboratory Evaluations: platelet count  
 
Stoppi[INVESTIGATOR_2121]: monitoring and stoppi[INVESTIGATOR_007] c riteria are 
presented in Section 7.1.[ADDRESS_113998] of 
ASOs.  
No adverse events related to renal function were reported 
in Study ISIS 505358 -CS3 Laboratory Evaluations: Serum creatinine, eGFR, 
urinalysis with microscopy and ACR assessed per the 
SoA tables  
 
Stoppi[INVESTIGATOR_2121]: Monitoring Schedule and Stoppi[INVESTIGATOR_102997] 7.1.[ADDRESS_113999] been reported with ASOs and 
reported in clinical studies with [COMPANY_004]3228836 (ISIS 
505358 -CS1 and ISIS 505358 -CS3).  
Injection site reactions were the most common study 
treatment -related AEs reported and were Grade 1 (mild) 
and Grade 2 (moderate) in severity.  Evaluations: Participants are assessed fo r injection site 
reactions at all visits during the on -treatment period.  
 
In order to minimize the risk of injection site reaction 
(ISR), injections should be rotated within each anatomical 
site or site(s) of injection should be changed 
administration -to-administration. Injection into areas with 
ongoing injection site reactions should be avoided.  
 
 
TMF-[ADDRESS_114000] increased 
susceptibility to SARS -CoV -2 infection.  Patients with uncomplicated viral hepatitis (i.e., 
without cirrhosis, or history of transplantation or current immunosuppressant use) don’t 
appear to be over -represented in hospi[INVESTIGATOR_102998] u nit cases of COVID -19, 
and therefore viral hepatitis isn’t considered a risk factor for a more severe course of 
COVID -19 [Fix, 2020; Boettler , 2020] . 
The actual risk of COVID -19 will vary by [CONTACT_103049], so study participants 
should follow any national or local hospi[INVESTIGATOR_102999], as well as specific 
recommendations from t heir healthcare providers.  
2.3.2.  Benefit Assessment  
Treatment of CHB with nucleos(t)ide analogues has been effective in reducing the long -
term complications of CHB, but evidence is emerging that HBsAg loss is associated with 
lower rates of hepatocellular carcino ma [ Kim, 2014; Yip, 2016]: Even patients who 
achieve complete viral su ppression experience significantly lower rates of hepatocellular 
carcinoma if they are able to achieve HBsAg loss.  Thus, there is a need in patients with 
CHB for a finite treatment that allows them to achieve immune control of their infection 
(functional cure, defined as HBsAg loss with HBV DNA suppression), removing the need 
for lifelong therapy and to improve long term disease outcomes, particularly development 
of hepatocellular carcinoma.  
[COMPANY_004]3228836 demonstrated target engagement in CHB patients who wer e not on treatment 
and in CHB patients on stable NA therapy. Overall, continued clinical development of 
[COMPANY_004]3228836 is supported by [CONTACT_103050] [ADDRESS_114001] therapeutic benefit to the  CHB population that will be 
included in this study. However, their participation could potentially contribute to the 
development of an improved treatment for patients with CHB.  
2.3.3.  Overall Benefit: Risk Conclusion  
Considering  the measures taken to minimiz e risk to participants in this study, the 
potential risks identified in association with [COMPANY_004]3228836  and from COVID -19 are 
balanced by [CONTACT_103051] . 
 
TMF-11822142  CONFIDENTIAL   
  212602  
25 
 3. OBJECTIVES AND ENDPOINTS  
Objectives  Estimands/Endpoints  
Primary  
Efficacy : To assess the effect of 12 
weeks of [COMPANY_004]3228836 on serum 
HBsAg levels  in participants with CHB  The Primary Estimand  supporting the primary objective of the study is 
defined as:  
• Population: Participants with CHB  who receive at least one 
dose of IP  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Variable: Achieving serum HBsAg level <LLOQ at any time 
point up to and including Week 12  without the use of PEG -
interferon or other immunomodu lator therapi[INVESTIGATOR_014]  
• Population -level summary: Percent of participants that achieve 
serum HBsAg level <LLOQ  
• Intercurrent events: Discontinuation of, interruption of, and 
adherence to IP will be ignored (treatment policy).  
The primary estimand is the percentage of participants with CHB 
receiving 300 mg [COMPANY_004]3228836 for 12 weeks (with at least one dose of 
IP) who achieve serum HBsAg level <LLOQ at any time point up to and 
including Week 12, without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014] , regardless of completing IP, interruptions in 
IP or adherence to IP.  
Secondary  
Efficacy: To assess sustainability of 
serum HBsAg loss by [CONTACT_23983]3228836 for 
up to 24 weeks off -treatment.  The Estimand supporting the objective is defined as:  
• Population:  Participants with CHB  who receive at least one 
dose of IP  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Variables :   
o Sustained HBsAg Response (HBsAg <LLOQ) for 
24 weeks after the planned end of  [COMPANY_004]3228836 treatment  
▪ HBsAg from Week 13 to Week 36 will be used to 
assess sustained HBsAg response after the planned 
end of  [COMPANY_004]3228836 treatment  without the use of PEG -
interferon or other immunomodulator therapi[INVESTIGATOR_014] .  
o Sustained HBsAg Response (HBsAg <LLOQ) for 
24 weeks after the actual end of [COMPANY_004]3228836 treatment  
▪ HBsAg for 24 weeks after end of actual treatment will 
also be used to assess sustained HBsAg response 
after the actual end of [COMPANY_004]3228836 treatment  without 
the use of PEG -interferon or other immunomo dulator 
therapi[INVESTIGATOR_014] . 
• Intercurrent  events: Discontinuation of, interruption of, and 
adherence to IP will be ignored (treatment policy).   
The group of estimands supporting this objective in participants with 
CHB receiving 300 mg [COMPANY_004]3228836 for 12 weeks (with  at least one 
dose of IP ) is the percentage of participants for each variable regardless 
of completing IP, interruptions in IP or adherence to IP,  without the use 
of PEG -interferon or other immunomodulator therapi[INVESTIGATOR_014] . 
TMF-11822142  CONFIDENTIAL   
  212602  
26 
 Objectives  Estimands/Endpoints  
Efficacy: To assess sustainability of 
serum HBsAg and HBV DNA loss by 
[CONTACT_23983]3228836 for up to 24 weeks off 
treatment.  The Estimand supporting the objective is defined as:  
• Population: Participants with CHB  who receive at least one 
dose of IP  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Variables:  
o Sustained  Virologic Response (HBsAg <LLOQ and HBV 
DNA <LLOQ) for 24 weeks after the planned end of 
[COMPANY_004]3228836 treatment  
▪ HBsAg and HBV DNA from Week 13 to Week 36 will 
be used to assess sustained virologic response after 
the planned  end of  [COMPANY_004]3228836 treatment  without the 
use of PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_014] . 
o Sustained  Virologic Response (HBsAg <LLOQ and HBV 
DNA <LLOQ) for 24 weeks after the actual end of 
[COMPANY_004]3228836 treatment  
▪ HBsAg and HBV DNA for 24 weeks after end of actual 
treatment will be used to assess sustained virologic 
response after the actual end of [COMPANY_004]322883 6 
treatment  without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014] . 
• Intercurrent events: Discontinuation of, interruption of, and 
adherence to IP will be ignored (treatment policy).   
The group of estimands supporting this objective in partic ipants with 
CHB receiving 300 mg [COMPANY_004]3228836 for 12 weeks (with  at least one 
dose of IP ) is the percentage of participants for each variable regardless 
of completing IP, interruptions in IP or adherence to IP,  without the use 
of PEG -interferon or other immu nomodulator therapi[INVESTIGATOR_014] . 
Efficacy : To assess the effect of [ADDRESS_114002] of 
12 weeks [COMPANY_004]3228836 on biomarkers and virus -specific antibody 
responses are defined as follows:   
• Population: Participants with CHB  who receive at least one 
dose of IP  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable 
nucleos(t)ide therapy)  
• Intercurrent events: Discontinuation of, interruption of, 
adherence to IP will be ignored (treatment policy) . PEG -
interferon or other immunomodulator therapi[INVESTIGATOR_103000] . 
1) Categorical Variables:  
• Achieving:  
o HBsAg <LLOQ over time  
o HBV DNA <LLOQ over time  
o HBsAg and HBV DNA <LLOQ over time 
• Categorical changes from baseline in HBsAg (e.g. <0.5, 0.5, 
1, 1.5, 3 log10 IU/mL) over time.  
• ALT>3X ULN at over time  
• HBe antibody (anti -HBeAg) levels over time  
Population summary: percentage of participants in each category.  
2) Continuous Variables:  
• Actual values and change from baseline over time for HBsAg 
and HBV DNA  
TMF-11822142  CONFIDENTIAL   
  212602  
27 
 Objectives  Estimands/Endpoints  
• HBs antibody ( anti-HBsAg) levels over time  
• Area under the curve (AUC) for ALT on treatment (12 weeks), 
during follow up (24 weeks), and on treatment + follow up (36 
weeks).  
 
Population summary: mean values and/or mean changes from baseline 
for each variable  
3) Time to Event Variable  
• Time to Maximum ALT (ALT must be greater than 3xULN) 
during 36 weeks of treatment + follow up  
 
Population summary: Turnbull  estim ate for median Time to Maximum ALT 
(>3xULN)  
The group of estimands supporting this objective in participants with CHB 
receiving 300  mg [COMPANY_004]3228836 for 12 weeks  (with at least one dose of IP)  
are the population summary for each variable  in the absence of  PEG -
interferon or other immunomodulator therapi[INVESTIGATOR_014] , regardless of completing 
IP, interruptions in IP , or adherence to IP .  
Safety  
Safety : To assess the safety and 
tolerability of [COMPANY_004]3228836 when dosed 
for 12 weeks in participants with CHB  Clinical assessments including, but not limited to vital signs, laboratory 
measurements and adverse events  
Exploratory  
CCI
TMF-11822142  CONFIDENTIAL   
  212602  
28 
 Objectives  Estimands/Endpoints  
4. STUDY DESIGN  
4.1. Overall Design  
This study is a Phase IIa, multi -centre open label exploratory study of the therapeutic 
mechanism of [COMPANY_004]3228836 in participants with HBeAg -negative CHB  on stable 
nucleos(t)ide therapy using repeat fine needle aspi[INVESTIGATOR_102990]  (see Section 1.2). 
The study consists of a single treatment arm : 
1. 300 mg [COMPANY_004]3228836 for 12 weeks (loading schedule on Day 4 and Day 11).  
Participants will continue to receive their stable nucleos(t)ide therapy.  
After the [ADDRESS_114003] -treatme nt follow -up 
period of 24 weeks.   An Independent Data Monitoring Committee (IDMC) will review the 
data (see Section 10.1.5 ). 
4.2. Scientific Rationale for Study Design  
The o verall objective of the study is to investigate the therapeutic mechanism of 
[COMPANY_004]3228836 in the liver using repeat fine needle aspi[INVESTIGATOR_103001] -emergent 
changes in A LT. 
Understanding the interplay between the virology of CHB and the host immune system 
will be key to the rational, evidence -based selection of biomarkers of response, 
optimisation of therapeutic approaches and selection of combination treatment regimens 
[Gill, 2019].  
Study ISIS 505358 -CS3 has already demonstrated efficacy of up to 4 weeks treatment with 
[COMPANY_004]3228836 on serum HBsAg levels in treatment naïve and nucleos(t)ide -contro lled 
participants, with concomitant reversible elevations in serum ALT, believed to be 
indicative of HBV -targeted immune responses against infected hepatocytes.  
CCI
TMF-11822142  CONFIDENTIAL   
  212602  
29 
 Additional comprehensive investigation of the mechanism of action of [COMPANY_004]3228836 in the 
liver co mpartment is essential:  
• To determine whether [COMPANY_004]3228836 has an immunomodulatory mechanism of 
action in addition to its previously described direct antiviral effects on HBV 
mRNA.  
• To investigate the relationship between [COMPANY_004]3228836 -mediated suppression of 
HBsAg, ALT flares and the potential for functional cure.  
• To investigate immunological and/or virological correlates of HBsAg -suppression 
that may enable future response -guided therapy .  
• To identify novel immunological pathways or targets with the potential  to improve 
functional cure rates when used in combination or sequence with [COMPANY_004]3228836.  
Study 212602 (B -Fine) will investigate 12 weeks treatment with 300 mg/ week 
[COMPANY_004]3228836 (including loading doses on Day 4 and Day 11 used in Study ISIS 505358 -
CS3).    
Rationale for study population  
In study 212602 (B -Fine), participants expected to have the highest chance of achieving 
HBsAg level <LLOQ with [ADDRESS_114004] 
study intrahepatic and peripheral virological and immunological correlates of HBsAg loss 
and treatment -emergent ALT elevations.  
• Patients on stable nucleos(t)ide therapy  
• Patients who are HBeAg -negative  
Selection of nucleos(t )ide-controlled CHB patients  
Efficacy of 4 weeks treatment with [COMPANY_004]3228836 has been investigated in Phase IIa study, 
ISIS 505358 -CS3, in both treatment naïve participants and participants on stable 
nucleos(t)ide therapy.  Both groups of study participants experienced declines in HBsAg, 
including some achieving HBsAg levels <LLOQ, followed by [CONTACT_103052] (refer 
to Investigator’s Brochure [ [COMPANY_004] Document Number 2019N425040_00 ]).   
Although there are some differences in regional treatment guidelines  for starting 
nucleos(t)ide therapy, most indicate the initiation of treatment at the onset of active 
hepatitis, defined as high levels of HBV DNA and elevate d ALT [ EASL , 2017; Sarin  2016; 
Terrault , 2018].  Treatment with nucleos(t)ides is very effective in controlling HBV 
replication and acute hepatitis over a treatment period of approximately 6 months, resulting 
in undetectable levels of HBV DNA in the blood and normalisation of ALT.  As these 
patients typi[INVESTIGATOR_103002], they are a common 
patient subpopulation within speciality hepatology centres and clinics.  
Patients whose infection is controlled by [CONTACT_103053](t)ides still have high levels of HBsAg in 
serum due to the presence of high levels of HBV cccDNA and integrated DNA in infected 
hepatocytes.  A recently completed [COMPANY_004] -sponsored Phase IIa study (205670) investigated 
safety, tolerability, pharmacokinetics and pharmacodynamics of a related HBV -targeted 
TMF-11822142  CONFIDENTIAL   
  212602  
30 
 antisense oligonucleotide ( ASO ), [COMPANY_004]3389404, in nucleos(t)ide -controlled participants 
with HBeAg -positive and HBeAg -negative CHB. Part 2 of the study enrolled 66 
participants (18 HBeAg -positive, 48 HBeAg -negative) in the Asia -Pacific region, 
including Hong Kong, China, Japan, Philippi[INVESTIGATOR_1651], Singapore and South Korea.  Mean (SD) 
baseline serum HBsAg was 2.94 (0.56) log 10 IU/ml, with 4/66 participants having baseline 
serum HBsAg levels above 10,000 IU/ml [[COMPANY_004] Document Number 2020N429086_00 ]. 
CHB patient s on stable nucleos(t) therapy have been selected for study [ADDRESS_114005] favourable benefit:risk profile for early PoM/PoC studies with 
experimental therapi[INVESTIGATOR_103003] [ Lok, 2017].  
Selection of HBeAg -negative patients  
The utility of serum HBsAg as a predictor of treatment response in CHB has been widely 
investigated, particularly in those treated with P EG-interferon s.  Lower serum HBsAg at 
baseline and rapid early declines on -treatment have both been associated with higher rates 
of sustained loss of HBsAg and functional cure [ Lee, 2018; Liu 2018].  Although the 
relationship between baseline serum HBsAg and response to [COMPANY_004]3228836 has yet to be 
established, it is reasonable to assume that participants with lower levels  of HBsAg at 
screening will be more likely to achieve HBsAg levels <LLOQ on treatment.  As HBeAg -
negative patients typi[INVESTIGATOR_103004] -positive 
patients, the HBeAg -negative population has been selected for study 212602 in order to 
enrich for potential responders.  
Previous [COMPANY_004] clinical experience in CHB supports the observation that serum HBsAg 
levels are lower in HBeAg -negative patients than HBeAg -positive patients.  In study ISIS 
505538 -CS3, there were a wide range of base line HBsAg levels reported across all 4 
Cohorts (entry criteria for serum HBsAg >50 IU/mL).  Final data from that study highlight, 
as expected, a lower baseline HBsAg level in HBeAg -negative than HBeAg -positive 
participants.  In Cohort 4 of study ISIS 5055 38-CS3, which included only HBeAg -negative 
participants on stable nucleos(t)ide therapy (n=7), baseline serum HBsAg levels ranged 
from 173.7 -30,943 IU/mL.  Only one participant in Cohort 4 had a baseline serum HBsAg 
level above 10,000 IU/mL [[COMPANY_004] Document N umber 2020N429086_00 ].  A recently 
completed [COMPANY_004] -sponsored Phase IIa study (205670) investigated safety, tolerability, 
pharmacokinetics and pharmacody namics of a related HBV -targeted ASO, [COMPANY_004]3389404, 
in nucleos(t)ide -controlled participants with HBeAg -positive and HBeAg -negative CHB.  
This study recruited 66 participants (18 HBeAg -positive, 48 HBeAg -negative) in the Asia -
Pacific region, including Hong K ong, China, Japan, Philippi[INVESTIGATOR_1651], Singapore and South 
Korea.  Mean (SD) baseline serum HBsAg was 2.86 (0.51) log 10 IU/mL in HBeAg -
negative participants compared to 3.04 (0.56) IU/ml in HBeAg -positive participants [[COMPANY_004] 
Document Number 2020N429086_00 ].  
Rationale for studying [ADDRESS_114006] from the blood.  The duration of suppression of HBsAg required to 
enable reconstitution of anti -HBV immunity is still unknown.  In study  ISIS 505358 -CS3 
treatment of participants with CHB on stable nucleos(t)ide therapy with 300 mg/week of 
TMF-11822142  CONFIDENTIAL   
  212602  
31 
 [COMPANY_004]3228836 for 4 weeks duration was associated with reductions in HBsAg.  Median 
decline in HBsAg from baseline over 4 weeks was -3.166 IU/ml, with two participants 
achieving HBsAg levels <LLOQ while on treatment, or shortly after.  Both of these 
participants saw reversable elevations in ALT to >3X ULN after HBsAg had fallen 
<LLOQ.   Of note, in participants that did not become HBsAg <LLOQ, reductions of 
HBsAg had not yet reached a plateau during treatment, suggesting that continued dosing 
has the potential to further reduce HBsAg levels.  Taken together, the data suggest that a 
longer duration of treatment with  [COMPANY_004]3228836 may be required t o increase the r ate of 
participants achieving HBsAg levels <LLOQ.   Twelve  weeks duration of trea tment with 
300 mg [COMPANY_004]3228836  has been selected as optimal  to assess the primary endpoint of 
achieving HBsAg < LLOQ in study 212602. Longer durations of treatment (up to 24 
week s) will be explored in other clinical trials during the  development of [COMPANY_004]3228836 in 
order to optimise efficacy in terms of sustained virological response and functional cure.  
Rationale for inclusion of fine needle aspi[INVESTIGATOR_103005], much of what is understood of the virology and immunobiology of CHB infection 
has come from studies of the peripheral blood compartment of infected patients in 
observational and a limited number of interventional clinical studies.  More recently, a 
small number of  studies using conventional liver biopsy or alternative liver -sampling 
techniques to study liver resident immune subtypes have revealed substantial differences 
between the systemic and liver compartments, including defective T -cell-mediated 
immunity agains t HBV in the liver of chronically infected patients [ Gill, 2019].  
Where liver biopsies were once considered routine in the diagnosis and monitoring of liver 
disease in patients  with CHB, they have been mostly replaced by [CONTACT_105] -invasive tests in 
recent years, limiting the opportunity to study the liver -resident immune subpopulations in 
clinical studies.  Research papers have recently described the use of fine needle aspi[INVESTIGATOR_4026] 
(FNAs ) as a rapid and better -tolerated alternative to conventional core biopsies for 
sampling intrahepatic immune cells, including T -cells and cells of the innate immune 
system, such as liver -resident NK cells.  This novel technique has been shown to be safe 
and effective for repeat sampling of the same patient over several weeks/months, 
permitting longitudinal analysis of immune responses to therapeutic interventions in 
clinical trials for the first time [ Gill, 2019; Tjwa , 2016; Sprengers , 2005 ]. 
In study 212602, it is proposed to perform a total of 5 FNAs at preselected timepoints (plus 
up to 1 optional FNA) during the 45 -week study duration  (see Section 1.2).  The  timing of 
FNAs has been selected to assess intrahepatic immunological changes at different stages 
of treatment with [COMPANY_004]3228836, and in the follow -up period ( Table 6) 
TMF-11822142  CONFIDENTIAL   
  212602  
32 
 Table 6 Timepoints for Fine Needle Aspi[INVESTIGATOR_103006] (Study 
Week)  Description  
1 Week -1 Baseline sample  
2 Week 3  Early on -treatment. Preceding anticipated marked declines in serum HBsAg 
level.  
3 Week 5  Anticipated start of HBsAg level <LLOQ in responders and start of ALT flare 
(Based on review of efficacy data in study ISIS 505358 -CS3).  
4 Week 13  End of treatment  
5 Week 36  End of follow -up 
6 
(Optional)  Any between Week 6 
and Week 36  To be determined following discussion between investigator and medical 
monitor. May be triggered by [CONTACT_103054].  
4.2.1.  Participant Input into Design  
A small group of patients with CHB were asked to review an example informed consent 
form in related study 209668. The patients provided feedback for more clarity in the 
informed consent form regarding the purpose of the study and optional assessments (e.g. 
biomarkers), mode of administration of [COMPANY_004]3228836, the study burden in both terms of 
visit schedule  and duration of visit.  Efforts to reduce the burden of visits were encouraged.  
Input from these patients will be incorporated into the Informed Consent Form.  The study 
team reviewed the blood collection timepoints and made changes to balance participan t 
burden with the data/timepoints needed for safety and efficacy analyses.  
Due to the feedback from patients that the number of visits may be challenging (weekly 
visits to the clinic/hospi[INVESTIGATOR_307]), the study team are working with countries/sites to provide an 
option where participants may use a centralised home nursing provider.  The home nursing 
providers will go to the participant, decreasing the number of times the participant must 
travel to/from the clinic/hospi[INVESTIGATOR_307].  Only selected visits will have the optio n to be performed 
as a home visit, these will include drug administration, blood draws, participant  
assessments and data collection. The full specifications of the home nursing services will 
be outlined in the SRM.  
4.3. Justification for Dose  
Dose Levels, Frequ ency and Duration  
Weekly dosing of [COMPANY_004]3228836 has been evaluated over a four -week dosing duration in 
both healthy volunteers (ISIS 505358 -CS1 study) and in participants with CHB (ISIS 
505358 -CS3 study).  In both studies, [COMPANY_004]3228836 was administered subcuta neously on 
Study Day 1, 4, 8, 11, 15, and 22.  The loading schedule (i.e. loading doses) in Week 1 
(Day 4) and Week 2 (Day 11) were included in order to accelerate the achievement of 
steady state concentration in the liver to increase the likelihood of obs erving anti -HBV 
activity during a short treatment duration.   
To date, the highest dose of [COMPANY_004]3228836 evaluated was 2700 mg over 4 weeks (450 mg 
per injection including loading doses ; n=3) in healthy volunteers, and 1800 mg over 4 
TMF-11822142  CONFIDENTIAL   
  212602  
33 
 weeks (300 mg per injecti on including loading doses; n=18) in participants with CHB. In 
treatment -naïve participants with CHB dosed with 300 mg per injection in ISIS 505358 -
CS3 study, continuous HBsAg declines were observed in many participants during 
[COMPANY_004]3228836 treatment, with tw o participants achieving HBsAg level <LLOQ that 
persisted for 102 and 28 days, respectively. In both participants who achieved HBsAg level 
<LLOQ, HBsAg subsequently became detectable after discontinuation of [COMPANY_004]3228836 
dosing.  Moreover, many participants had declining HBsAg levels that hadn’t plateaued by 
[CONTACT_57627].   
Similar responses were observed in participants in Study ISIS 505358 -CS3 on stable 
nucleos(t)ide therapy.  Three of five [COMPANY_004]3228836 -treated participants (60%) achieved 
HBsAg reduct ions >3 log 10 IU/mL.  Two of five participants (40%) treated with 300 mg 
[COMPANY_004]3228836 achieved HBsAg <LLOQ (0.05 IU/mL).  One participant reached HBsAg 
levels <LLOQ on Day 23, but this was not sustained.  HBsAg was detectable on the Day 
85 and Day 113 visits .  One participant had HBsAg <LLOQ on Day 36 and remained 
<LLOQ as of the Day [ADDRESS_114007] that a longer duration of 
[COMPANY_004]3228836 therapy may be required to both increase the rate of participants achieving 
and sustaining HBsAg levels <LLOQ.  
Study 212602 will explore weekly dosing of [COMPANY_004]3228836 300 mg for 12 weeks (with 
the loading doses) in participants on stable nucleos(t)ide therapy.  
Co-administration of [COMPANY_004]3228836 and Nucleos(t)ide Analogues  
[COMPANY_004]3228836 is unlikely to be a vic tim or perpetrator of drug -drug interactions when 
administered with nucleos(t)ide analogues due to their divergent absorption, distribution, 
metabolism, and excretion pathways.  
Drug -drug interactions with [COMPANY_004]3228836 as victim:  
Upon entry into the system ci rculation, [COMPANY_004]3228836 rapi[INVESTIGATOR_103007] 
(approximately 95%) to serum proteins and is then rapi[INVESTIGATOR_103008]. 
[COMPANY_004]3228836 enters hepatic cells through target -mediated endocytosis and enters renal 
cells through micropi[INVESTIGATOR_103009] [ Geary , 2008; Bennett , 2010].  [COMPANY_004]3228836 is eliminated 
primarily via nucleolytic degradation by [CONTACT_103055] [ Geary , 2008].  None 
of these processes is inhibited or induced by [CONTACT_34677] -molecule drugs including nucleos(t)ide 
analogues (e.g. tenofovir, entecavir, lamivudine, adefovir and telbivudine).  
In Cohorts 1 -3 of the ISIS 505358 -CS3 study, treatment -naïve participants were sta rted on 
tenofovir after treatment ended; in Cohort 4, where participants were nucleos(t)ide 
experienced, the majority of participants entered the study on entecavir.  Clinical data from 
this study suggest that co -administration of entecavir is unlikely to impact plasma PK of 
[COMPANY_004]3228836.  [COMPANY_004]3228836 was co -administered with entecavir throughout the treatment 
period in 4 participants in Cohort 4 while administered alone in 18 participants in Cohorts 
1 to 3.  [COMPANY_004]3228836 plasma concentration was comparable with  entecavir (n=4) and 
without entecavir (n=18).  Dose normalization was applied to Cohort 1 as 150 mg of 
[COMPANY_004]3228836 was administered in Cohort 1 as compared to 300 mg in Cohorts 2 to 4.  
TMF-11822142  CONFIDENTIAL   
  212602  
34 
 Drug -drug interactions with [COMPANY_004]3228836 as perpetrator:  
Tenofovir, entecavir, and other nucleos(t)ide analogues circulated in the blood stream with 
little binding to serum proteins [ Bristol -Myers Squibb , 2018; [COMPANY_009] , 2018]. Tenofovir, 
entecavir, lamivudine, adefovir and telbivudine are predominantly renally eliminated from 
systemic circulation [ Epi[INVESTIGATOR_54736] , 2002; Kearney , 2004; Hepsera , 2012; Tyzeka , 2013; 
Baraclude , 2015; Bristol -Myers Squibb , 2018; [COMPANY_009] , 2018]. These [ADDRESS_114008] been reported to be 
mediated by [CONTACT_103056]: the organic anion transporter (OAT) 
1, OAT3, the organic cation transporter (OCT) 1, and OCT2 [ Cihlar , 2001; Cihlar , 2004; 
Servais , 2006; Uwai , 2007; Minuesa , 2009; Yanxiao , 2011; Xu, 2013]. It has been shown 
that 2' -MOE ASO is neither a substrate nor an inhibitor of OAT1, OAT3, OCT1 and OCT2 
[Yu, 2016; Shemesh , 2017]. Therefore, although [COMPANY_004]3228836 was shown to be 
extensively distributed into the kidney in  non-clinical studies, it is unlikely to interact with 
tenofovir, entecavir, lamivudine, adefovir, telbivudine, or other nucleos(t)ide analogues.  
Clinical data from ISIS [ADDRESS_114009] efficacy  and safety profiles.  Given the long plasma and tissue half -life 
of [COMPANY_004]3228836 (approximately 3 weeks), there is a period of at least several weeks during 
which there was a substantial presence of both drugs in the plasma, liver and other tissues.  
Potent  reduction of HBV DNA was observed following initiation of tenofovir in all 
participants.  There were no obvious differences in tenofovir potency and efficacy in 
participants who received 150 mg of [COMPANY_004]3228836 (Cohort 1), 300 mg of [COMPANY_004]3228836 
(Cohorts 2 and  3), and placebo (no [COMPANY_004]3228836).  There were no adverse event or clinical 
laboratory results that may indicate a change in tenofovir safety profile due to drug -drug 
interaction with [COMPANY_004]3228836.  
4.4. End of Study Definition  
A participant is considered to have c ompleted the study if he/she has completed all phases 
of the study including the last visit.  
The end of the study is defined as the date of the last visit of the last participant in the study.  
5. STUDY POPULATION  
Prospective approval of protocol deviations to  recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
TMF-[ADDRESS_114010] 18 years of age at the time of signing the informed consent. [if 
country/site age requirements for consent differ, the more stringent (e.g., higher 
age) restriction will be required for that country/site].  
TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS  
2. Participants who have d ocumented chronic HBV infection ≥6 months prior to 
screening AND currently receiving stable nuc leos(t)ide analogue therapy, 
defined as no changes to their nucleos(t)ide regimen from at least 6 months 
prior to screening and with no planned changes to the stable regimen over the 
duration of the study  
3. Plasma or serum HBsAg concentration >100 IU/mL.  
4. Plasma or serum HBV DNA concentration must be adequately suppressed, 
defined as plasma or serum HBV DNA <90 IU/mL  
5. HBeAg -negative  
6. Alanine Transaminase (ALT) ≤[ADDRESS_114011]  
SEX  
7. Male and/or Female  
a. A male participant is eligible to participate if they agree to the following 
during the intervention period and for at least [ADDRESS_114012] dose of 
study treatment  
i. Refrain from donating sperm  
ii. AND be abstinent from heterosexual intercourse as their 
preferred and usual lifestyle (abstinent on a long term and 
persistent basis) and agree to remain abstinent OR Must agree 
to use contraception/barrier as detailed below  
1. Agree to use a male condom [and should also be advised of 
the benefit for a female partner to use a highly effective 
method of contraception as a c ondom may break or leak] 
when having sexual intercourse with a woman of 
childbearing potential who is not currently pregnant  
b. A female participant is eligible to participate:  
i. If she is not pregnant or breastfeeding  
ii. AND at least one of the following conditio ns applies:  
1. Is not a woman of childbearing potential (WOCBP)  
2. OR is a WOCBP and using a contraceptive method that is 
highly effective (with a failure rate of <1% per year), 
preferably with low user dependency during the intervention 
period and for at least  [ADDRESS_114013] dose of study 
intervention [additional evaluation (e.g., amenorrhea in 
athletes, birth control) should also be considered]  
2. AND a negativ e highly sensitive pregnancy test [urine or 
serum] within [ADDRESS_114014] dose of study 
treatment  
Contraceptive use by [CONTACT_103057].  
Additional requirements for pregnancy testing during and after study 
intervention are included in Appendix 4  of the protocol  
The investigato r is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnancy  
 
INFORMED CONSENT  
8. Capable of giving signed informed consent as described in Section 10.1 which 
includes compliance with the requirements and restrictions listed in the  
informed consent form (ICF) and in this protocol.  
5.2. Exclusion Criteria  
MEDICAL CONDITIONS  
1. Clinically significant abnormalities, aside from chronic HBV infection in medical 
history (e.g., moderate -severe liver disease other than chronic HBV, acute coronary 
syndrome within 6 months of screening, major surgery within 3 months of 
screening, signifi cant/unstable cardiac disease, uncontrolled diabetes, bleeding 
diathesis or coagulopathy) or physical examination  
2. Co-infection with:  
• Current or past history of Hepatitis C virus (HCV)  
• Human immunodeficiency virus (HIV)  
• Hepatitis D virus (HDV)  
3. History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by  
• Both Aspartate aminotransferase (AST) -Platelet Index (APRI) >2 and 
FibroSure/FibroTest result >0.7  
i. If only one parameter (APRI or FibroSure/FibroTest) result is 
positive, a discussi on with the Medical Monitor is required before 
inclusion in study is permitted  
• Regardless of APRI or Fibrosure/FibroTest score  participants will be 
excluded from the study if their past history includes one of the following 
criteria : 
TMF-11822142  CONFIDENTIAL   
  212602  
37 
 i. Liver biopsy showing M etavir 4 or equivalent  
ii. Liver stiffness >12 kPa  
4. Diagnosed or suspected hepatocellular carcinoma as evidenced by [CONTACT_716]  
• Alpha -fetoprotein concentration ≥200 ng/mL  
• If the screening alpha fetoprotein concentration is ≥50 ng/mL and <200 
ng/mL, the absence of liver mass must be documented by [CONTACT_47429] [ADDRESS_114015] 5 years with the exception of specific 
cancers that are cured by [CONTACT_78043] (e.g., skin cancer). Participants under 
evaluati on for possible malignancy are not eligible.  
6. History of vasculitis or presence of symptoms and signs of potential vasculitis [e.g., 
vasculitic rash, skin ulceration, repeated blood detected in urine without identified 
cause] or history/presence of other di seases that may be associated with vasculitis 
condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing 
polychondritis, mononeuritis multiplex)  
7. History of extrahepatic disorders possibly related to HBV immune conditions (e.g., 
nephroti c syndrome, any type of glomerulonephritis, polyarteritis nodosa , 
cryoglobulinaemia, uncontrolled hypertension ) 
8. Positive  (or borderline positive)  ANCA at screening by [CONTACT_103058]’t be an exclusion 
criterion - but if results are borderline positive or positi ve: 
• Participants that meet this criteria may be considered for inclusion 
following:  
i. Analysis of  MPO -ANCA [pANCA] and PR3 -ANCA [cANCA] 
AND   
ii. A discussion with the Medical Monitor to review participant’s 
complete medical history to ensure no past history or current 
manifestations of a vasculitic/inflammatory/auto -immune condition  
9. Low C3 at screening or baseline  AND evidence of  past history or current 
manifestations of vasculitic/inflammatory/auto -immune conditions  
• All participants with low C3 at screening sho uld have their medical history 
discussed with the Medical Monitor prior to enrolment  
10. History of alcohol or drug abuse/dependence  
• Current alcohol use as judged by [CONTACT_103059]  
• History of or current drug a buse/dependence as judged by [CONTACT_103060]  
i. Refers to illicit drugs and substances with abuse potential. 
Medications that are used by [CONTACT_103061], whether 
over-the-counter or through prescription, are acceptable and would 
not meet the exclusion criteria  
 
TMF-11822142  CONFIDENTIAL   
  212602  
38 
 PRIOR/CONCOMITANT THERAPY  
11. Currently taking, or took within 3 months of screening, any immunosuppressing 
drugs (e.g., prednisone), other than a short course of therapy (≤2 weeks) or 
topi[INVESTIGATOR_2855]/inhaled steroid use.   
12. Participants for whom immunosuppressive treatment is not advised, including 
therapeutic doses of steroids, will be excluded  
13. Currently taking, or took within 12 months of screening, any interferon -containing 
therapy.  
14. Participants requiring anti -coagulation  therapi[INVESTIGATOR_014]  (for example warfarin, Factor Xa 
inhibitors or anti -platelet agents like clopi[INVESTIGATOR_7745]) .   
 
PRIOR/CONCOMITANT THERAPY  
15. The participant has participated in a clinical trial and has received an 
investigational  product within the following time period prior to the first dosing 
day in the current study: 5 half -lives (if known) or twice the duration (if known) of 
the biological effect of the study treatment (whichever is longer) or 90 days (if half -
life or duratio n is unknown).  
16. Prior treatment with any oligonucleotide or small interfering RNA (siRNA) within 
[ADDRESS_114016] dosing day  
 
DIAGNOSTIC ASSESSMENTS  
17. Fridericia’s QT correction formula (QTcF) ≥450  msec (if single electrocardiogram 
[ECG] at screening shows QTcF 450 msec, a mean of triplicate measurements 
should be used to confirm that participant meets exclusion criterion).  
18. Laboratory results as follows  
• Serum albumin <3.5 g/dL  
• Glomerular filtration rate (GFR) <60 mL/min /1.73m2 as calculated by [CONTACT_103062] -EPI [INVESTIGATOR_14420].  
• INR >1.25  
• Platelet count <140 X 109/L 
• Total bilirubin >1.[ADDRESS_114017]  
i. For participants with benign unconjugated hyperbilirubinemia with 
total bilirubin >1.[ADDRESS_114018], discussion for inclusion to the study is 
required with the Medical Monitor  
• Urine albumin to creatinine ratio (ACR) ≥0.03 mg/mg (or ≥30 mg/g). In the 
event of an ACR above this threshold, eligibility may be confirmed by a 
second measu rement  
i. In cases where participants have low urine albumin and low urine 
creatinine levels resulting in a urine ACR calculation ≥ 0.03 mg/mg 
(or ≥30 mg/g), the investigator should confirm that the participant 
does not have a history of diabetes, hypertensio n or other risk 
factors that may affect renal function and discuss with the Medical 
Monitor, or designee  
 
TMF-11822142  CONFIDENTIAL   
  212602  
39 
 OTHER EXCLUSIONS  
19. History of/sensitivity to [COMPANY_004]3228836 or components thereof or a history of drug or 
other allergy that, in the opi[INVESTIGATOR_43184], 
contraindicates their participation  
5.3. Lifestyle Considerations  
5.3.1.  Alcohol and Tobacco  
During each dosing session, participants will abstain from alcohol for [ADDRESS_114019] the clinic.  
Participants who use tobacco products will be instructed that use of nicotine -containing 
products (including nicotine patches and other delivery devices such as vaporizers) will 
not be permitted while they are in the clinical unit.  
5.3.2.  Activity  
Participants will abstain from strenuous exercise for 48 hours before each blood 
collection for clinical l aboratory tests.  For the duration of the study, until final follow -up, 
participants are encouraged to refrain from changing their activity beyond that which they 
normally perform.  Additionally, participants will abstain from taking creatine -containing 
exercise supplements for all parts of the study.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently enrolled. A minimal set of screen failure information is required 
to ensure  transparent reporting of screen failure participants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography, screen 
failure de tails, eligibility criteria, any protocol deviations and any serious adverse events 
(SAEs).  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
not be rescreened unless discussed and agreed with the Medical Monitor . Individuals who 
fall out of the screening window, may be rescreened at the discretion of the investigator 
and site.  
5.5. Criteria for Temporarily Delaying Administration of Study 
Intervention  
See Section 7.1 for guidance on treatment hold and criteria for temporarily delaying 
[COMPANY_004]3228836.  
TMF-11822142  CONFIDENTIAL   
  212602  
40 
 6. STUDY INTERVENTION (S) AND CONCOMITANT 
THERAPY  
Study intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo , or medical device (s) intended to be administered to a study participant according 
to the study protocol.  
6.1. Study Intervention(s) Administered  
The site of injection will be recorded for each participant and dose(s).  Sites of injection 
are listed in order of preference and are a guide for the clinical staff.  
1. Abdominal quadrants  
2. Thighs  
3. Outer area of the upper arms  
4. Buttocks  
Injections should be rotated within each anatomical site or site(s) of injection should be 
changed administration -to-administration. Injection into areas with ongoing injection site 
reactions should be avoided.  
6.2. Preparation/Handling/Storage/Accountability  
The investig ator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
Only participants enrolled in the  study may receive study intervention and only authorized 
site staff may supply or administer study intervention.  All study interventions must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area 
in accordance with t he labelled storage conditions with access limited to the investigator 
and authorized site staff.  
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation,  and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused study intervention are 
provided in the Study Reference Manual .  
CCI
TMF-[ADDRESS_114020] and the generation of aerosols or mists.  In the case of unintentional 
occupational expos ure notify the monitor, Medical Monitor and/or [COMPANY_004] study contact.  
A Material Safety Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the investigator, 
where this is requir ed by [CONTACT_1207], or is available upon request from [COMPANY_004].  
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is an open -label study with one treatment arm.  Randomization and blinding are not 
applicable.   As the study is unblinded, the risk of potential bias will be mitigated by 
[CONTACT_103063], where feasible, the  [COMPANY_004]  central team ’s exposure to virological biomarker  
results , including HBsAg, HBsAb and HBV DNA , is limited .  Details will be included in 
separat e blinding plans.  
6.4. Study Intervention Compliance  
When participants are dosed at the site, they will receive study intervention directly from 
the investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents.  The dose of study 
intervention and study participant identification will be confirmed at the time of dosing by 
a member of the study site staff other than the person administering the study intervention.  
6.5. Dose Modi fication  
Dose modifications are not planned for this study.  
6.6. Continued Access to Study Intervention after the End of the 
Study  
No intervention is planned at the end of the study, although participants may be asked to 
enrol in a long -term roll -over study bas ed on their response.  
6.7. Treatment of Overdose  
For this study, any dose of [COMPANY_004]3228836  greater than 300 mg within a 24 -hour time period 
will be considered an overdose.  
[COMPANY_004] does not recommend specific treatment for an overdose.  
In the event of an overdose, the investigator should:  
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for AE/SAE and laboratory abnormalities until 
[COMPANY_004]3228836 can no longer be detected systemically (at least 105 days).  
TMF-[ADDRESS_114021] dose of 
study intervention if requested by [CONTACT_1689] (determined on a case -by-case 
basis).  
4. Document the quantity of the excess dose as well as the duration of the overdosing in 
the CRF.  
Decisions regarding dose in terruptions or modifications will be made by [CONTACT_103064].  
6.8. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines,  
vitamins, and/or herbal supplements or other specific categories of interest)  that the 
participant is receiving at the time of enrollment or receives during the study must be 
recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency  
The Medical Monitor should be contact[CONTACT_26237].  
Concomitant medications, including nucleos(t)ides, should be recorded.  
Traditional Chinese medicine (TCM) and/or acupuncture as it relates to CHB therapy 
should be avoided during the duration of the study.  If participants report use of TCM 
and/or acupuncture, then details must be recorded in the concomitant medication case 
report form (CRF).  
6.8.1.  Nucleos(t)ide Treatment during and after the End of the Study  
The investigator is responsible for ensuring that consideration has been given to the care 
of the participant’s medical condition, and that participants are able to continue their 
therapy over th e duration of the study.  
The investigator is responsible for ensuring that consideration has been given to the post -
study care of the participant’s medical condition, whether or not [COMPANY_004] is providing specific 
post-study treatment.  
6.8.2.  Prohibited Medications and  Non-Drug Therapi[INVESTIGATOR_103010]:  
• PEG -interferon or other immunomodulating therapi[INVESTIGATOR_014]  
• Immunosuppressing drug (e.g., prednisone) use >2  weeks duration from 3  months 
prior to Screening through the fi nal Follow -up visit (see Section 5.2), unless 
required for safety  
• Prior treatment with any oligonucleotide or small interfering RNA (siRNA) within 
[ADDRESS_114022] dosing  through the final Follow -up visit  
TMF-11822142  CONFIDENTIAL   
  212602  
43 
 • Creatine -containing gym supplements  
• Anti-coagulation  therapi[INVESTIGATOR_014] (for example warfarin, Factor Xa inhibitors or 
anti-platelet agents like clopi[INVESTIGATOR_7745]) .  Note: occasional use of aspi[INVESTIGATOR_103011], 
please consult the medical monitor if needed.   
7. DISCONTINUATION OF S TUDY INTERVENTION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention  
A participant may withdraw from the study treatment at any time at his/her own request or 
may be withdrawn at any time at the discretion of the Investigator for  safety, behavioural 
or administrative reasons.  In rare instances, it may be necessary for a participant to 
permanently discontinue (definitive discontinuation)  study intervention .  Participants that 
withdraw from treatment for any reason should be encouraged to complete all their on -
treatment and follow -up visits and assessments.  Should the participant not wish to continue 
with weekly visits in the on -treatment window, a reduced visit schedule may be considered. 
The reduced visit schedule should in clude Weeks 3, 5 and 12 and all specified assessments 
as a minimum.  Every effort should be made to complete the early termination (ET) study 
procedures and observations if the participant does not enter post -treatment follow -up. 
Any laboratory parameter t hat meets the stoppi[INVESTIGATOR_103012] (Section 7.1.1 - Section 7.1.4 ), participants 
should be monitored until laboratory abnormalities resolve, stabilize, or return to within 
baseline values  (i.e., p re-dose) as indicated.  The participant must then attend the visits 
specified in the SoA.  See the SoA for data to be collected at the time of discontinuation of 
study intervention and follow -up and for any further evaluations that need to be completed.  
7.1.1.  Liver Chemistry Monitoring and Stoppi[INVESTIGATOR_97175], and increased monitoring criteria have been designed to assure 
participant safety and to evaluate liver event etiology.  Study intervention will be 
discontinued for a participant if  the liver stoppi[INVESTIGATOR_23893].  
Discontinuation of study intervention for abnormal liver tests is required when:  
• a participant meets one of the conditions outlined in Table 7. 
• when in the presence of abnormal liver chemistries not meeting protocol -specified 
stoppi[INVESTIGATOR_004], the investigator believes study intervention discontinuation is in the 
best interest of the participant.  
Table 7 lists the criteria for withholding or discontinuing the study medication in a study 
participant with elevation of ALT.  Additional testing will be performed (see safe ty follow -
up procedures for participants who meet increased monitoring or stoppi[INVESTIGATOR_3418]), and the 
participant monitored until liver chemistry abnormalities resolve, stabilize, or return to 
within baseline values.  The participant must then attend the f ollow -up visits specified in 
the SoA.  
TMF-[ADDRESS_114023] the participant evaluated (within 24 hours) for repeat 
assessment of liver chemistries and additional testing and close monitoring (a specialist or 
hepatology consultation is recommen ded).  Participants must be monitored weekly until 
liver chemistry abnormalities (ALT, AST, alkaline phosphatase, bilirubin) resolve, 
stabilize, or return to within baseline values.  Upon completion of the safety follow -up 
procedures (see below), the parti cipant must attend the follow -up visits specified in the 
SoA.  
Table [ADDRESS_114024] ≤ ALT <12x ULN  
and 
Bilirubin ≤1.5x ULN  
and 
INR ≤1.5 (if available)  Monitor twice weekly  
Additional lab assessments  Permanently discontinue IMP if 
ALT >10x ULN >4 weeks  
 
 
ALT 12x ULN  
and 
Bilirubin ≤1.5x ULN  
and 
INR ≤1.5 (if available)  Hold dose  
Monitor twice weekly  
Additional lab assessments if not 
already done  
Take off hold:  150 mg SC weekly 
when ALT <10x ULN; increasing 
dose to 300 mg (if applicable) 
should be agreed with Medical 
Monitor   
Permanently discontinue IMP if 
any of the following apply:  
• ALT 10x ULN >4  weeks  
• ALT 12x ULN recurs after 
IMP taken off hold  
ALT 3x ULN  
and 
1.5x ULN <bilirubin ≤2x ULN 
(>35%  direct)  
and 
INR ≤1.5 (if available)  Hold dose  
Monitor twice weekly  
Additional lab assessments if not 
already done  
Take off hold:  150 mg SC weekly 
when bilirubin returns to <1.5x 
ULN; increasing dose to 300 mg 
(if applicable) should be agreed 
with Medical Monitor   
Permanently discontinue IMP if 
the following recurs after IMP 
taken off hold : 
1.5x ULN <bilirubin ≤2x ULN 
(>35%  direct)  
And 
INR 1.5 (if available)  
ALT 3x ULN and any of the 
following apply:  
• bilirubin >2x ULN 
(>35%  direct)  
• associated with the 
appearance  
or worsening of 
hepatitis symptoms  
• INR >1.5  (if available)    
Permanently discontinue IMP  
 
Monitor twice weekly until stable 
ALT 
 
Additional lab assessments if not 
already done  
ALT = alanine aminotransferase; IMP = investigational medicinal product; ULN = upper limit of normal  
*Notes:  
• Any abnormal laboratory parameters that meet the criteria for individual treatment 
discontinuation must be confirmed by [CONTACT_103065] a new collection of blood samples 
as soon as possible.  
TMF-11822142  CONFIDENTIAL   
  212602  
45 
 • Any clinically significant  deterioration from the baseline in the liver parameters 
must be confirmed by [CONTACT_103043], total bilirubin, direct bilirubin, and  INR (if 
available).  
• If one criterion in the list above is met and confirmed by [CONTACT_103066], further 
treatment may be discontinued for this participant after discussion with the 
Medical Monitor.  Results of retesting must be evaluated before the next dose i s 
administered.  
• Monitor participant until liver chemistry abnormalities resolve, stabilize, or return 
to within baseline values . 
• Cases such as Gilbert  syndrome , where baseline bilirubin values are high, should 
be discussed with the medical monitor, to assess if it is a case of  drug-induce liver 
injury  (DILI ) or the participant may continue with dosing.  
The procedures listed below are to be followed if a participant meets any of the liver 
chemistry stoppi[INVESTIGATOR_103013] 7: 
Notify the Medical Monitor within 24  hours of learning of the abnormality to confirm the 
participant’s study treatment cessation and follow -up. 
Complete the Liver Event ca se report form (CRF).  
Complete the “Safety Follow -up Procedures” listed below.  
Safety Follow -up Procedures for Participants Who Meet Any of The Liver 
Monitoring and Stoppi[INVESTIGATOR_2121]:  
Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  
o Hepatitis E IgM antibody ; 
o Hepatitis B virus DNA load ; 
o Hepatitis C virus RNA load ; 
o Hepatitis D virus antibod y. 
• Obtain a blood sample for pharmacokinetic (PK) analysis as soon as possible 
following the occurrence of an event. Record the date/time of the PK blood sample 
collection and the date/time of the last dose of study treatment prior to blood sample 
collecti on on the CRF. If the date or time of the last dose is unclear, provide the 
participant’s best approximation. Instructions for sample handling and shippi[INVESTIGATOR_103014] (SRM).  
• Serum creatine phosphokinase (CPK) and lactate deh ydrogenase (LDH).  
• Review fractionated bilirubin  
• Assess eosinophilia  
TMF-11822142  CONFIDENTIAL   
  212602  
46 
 • Record the appearance or worsening of clinical symptoms of hepatitis (fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or eosinophilia) 
as relevant on the Adverse Event (AE) CRF.  
• Record use of concomitant medications, acetaminophen, herbal remedies, other over 
the counter medications, or putative hepatotoxins on the Concomitant Medications 
CRF.  
• Record alcohol use on the Liver Events CRF.  
The following are required for participants who meet the ALT and bilirubin 
stoppi[INVESTIGATOR_103015] . 
• Anti-nuclear antibody, anti -smooth muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies and quantitative total immuno globulin G (IgG or 
gamma globulins).  
• Serum acetaminophen adduct high performance liquid chromatography 
(HPLC) assay (quantifies potential acetaminophen contribution to liver injury 
in participants with definite or likely acetaminophen use in the preceding 
week [ James , 2009]).  
• Liver imaging (ultrasound, magnetic resonance, or computerized tomography) 
or Liver biopsy to evaluate liver disease.  
o The Liver Imaging an d/or Liver Biopsy CRFs are also to be completed if these 
tests are performed.  
7.1.2.  Drug Induced Vascular Inflammation and Complement Stoppi[INVESTIGATOR_103016], results should be confirmed with a repeat sample 
collection and analysis , and if confirmed, further evaluation for alternative causes should 
be pursued in consultation with the Medical Monitor.  
Repeat sample collection of C3, C4, Bb, C5a would be triggered by [CONTACT_103067] (2+ haematuria; increasing urine ACR; 
vasculitic or purpuric rash; peripheral neuropathy; jaundice). Additional complement 
analyses for example CH50, Factor B level, Factor H level, sC5b -9 should also be 
considered in discussion with the Medical Monitor and Safety Panels.  
1. Persisting & deteriorating longitudinal trends in change from baseline for 
C3 and/or C4 defined as:  
a. If participant’s baseline C3 and/or C4 is within  the lab’s normal range at 
baseline: there is a sequential decline in C3 and/or C4 once l evels have 
fallen below the lower limit of normal ( LLN ) for ≥4 weeks OR  
b. If participant’s baseline C3 and/or C4 is below  the lab’s LLN at baseline: 
there is further sequential decline in C3 and/or C4 for ≥4 weeks OR  
c. Regardless of baseline C3 and/or C4 level : there is a ≥80% reduction  in 
the participant’s C3 and/or C4 level at any point  
AND  
d. There is an associated ≥3-fold increase  in Bb and/or C5a from 
participant’s baseline OR  
TMF-11822142  CONFIDENTIAL   
  212602  
47 
 e. There are associated biochemical sequelae for example, a rising high 
sensitivity C -reactive protein ( hs-CRP ); rising monocyte chemoattractant 
protein ( MCP -1); new thrombocytopenia, new renal impairment with no 
other explanation such as intercurrent infection OR  
f. There are associated clinical sequelae, for example, ≥2+ haematuria; 
increasi ng urine ACR; vasculitic or purpuric rash; peripheral neuropathy; 
jaundice OR  
g. There is new cANCA or pANCA positivity  
 
2. Persisting & deteriorating longitudinal trends in change from baseline for 
Bb and/or C5a where  
a. There is a ≥3 -fold increase in Bb and/or C5a over baseline  
AND  
b. This is persisting or increasing week on week in sequential data plots OR  
c. There are associated biochemical sequelae for example, a rising hs -CRP; 
rising MCP -1, new thrombocytopenia, new renal impairment with no 
other explanation such as intercurrent infection OR  
d. There are associated clinical sequelae, for example, ≥2+ haematuria; 
increasing urine ACR, vasculitic or purpuric rash; peripheral neuropathy; 
jaundice or any combination of these OR  
e. There is new cANCA or pANCA positivity  
Treatment Hold/Treatment Discontinuation  
• Hold study treatment during evaluation of alternative causes for decreased C3 
and/or C4 associated with increased inflammatory markers including one or more 
of hs -CRP, MCP -1, Bb and C5a  
• Discontinue study treatment p ermanently  if persistent change from baseline 
(≥4 weeks) in biomarker pattern ( decreased C3/C4 associated with increased 
inflammatory markers including one or more of hs -CRP, MCP -1, Bb, C5a)  
without clear alternative explanation.  
• Discontinue study treatmen t permanently if suspect clinical sequelae of  
complement activation, drug induced vascular in flammation , vasculitis or auto -
immunity regardless of biomarkers changes or persistence.  
7.1.3.  Haematological Stoppi[INVESTIGATOR_42224] a participant develops signs or sympt oms of thrombocytopenia, obtain a platelet count 
(local lab) as soon as possible and hold dosing until the platelet count is confirmed.  
If the platelet count is uninterpretable or  a decreasing trend is noted  below LLN reference 
range, re -check the platelet  counts as soon as possible  (the investigator may, at their 
discretion, opt to have the participant come to their next scheduled visit OR ask the 
participant to come earlier than their scheduled visit, as they feel appropriate based on 
review of the partic ipant’s clinical presentation and laboratory result s). Samples showing 
platelet clumpi[INVESTIGATOR_103017].  
TMF-11822142  CONFIDENTIAL   
  212602  
48 
 Participants with platelet values below 75 x 109/L will undergo further assessment 
including, but not necessarily limited to, anti -platelet an tibodies.  If the participant has a 
positive anti -platelet antibody, study treatment should be discontinued permanently.  
Monitor until platelet abnormalities resolve, stabilize, or return to within baseline values.  
Table 8 Haematological Stoppi[INVESTIGATOR_103018]  
75 X 109/L ≤ 
Platelets <100 X 
109/L Monitor weekly, results of local platelet 
count must be available prior to dosing  Hold treatment until platelets return to  100 
x109/L 
[if positive for anti -platelet antibodies, study 
treatment should be discontinued immediately]  50 X 109/L ≤ 
Platelets1 <75 X 
109/L Monitor every 2 -3 days until three 
successive measurements 75 x109/L, 
then weekly  
Assess anti -platelet antibodies  
<50 x 109/L Monitor daily until 25 x109/L, monitor 
every 2 -3 days until three successive 
measurements 75 x109/L, then weekly 
until platelets ≥100 x109/L 
Assess anti -platelet antibodies  Discontinue treatment permanently  
Glucocorticoids recommended (unless the 
partici pant has a medical contraindication to 
receiving glucocorticoids), and discontinuation of 
any antiplatelet medicinal 
products/NSAIDs/anticoagulants  
7.1.4.  Drug Induced Kidney Injury (Renal) Stoppi[INVESTIGATOR_103019]  
• Hold study treatment in participants who develop ACR ≥0.5 mg/mg (500 mg/g), or 
eGFR >25% reduction from baseline, pending consultation with the Medical 
Monitor and further evaluation of the cause.  
o If a dose is held, once eGFR increases to within baseline, ACR decreas es to 
<0.5 mg/mg (500 mg/g), or the underlying cause of the decline in renal 
function is corrected, weekly dosing may be reinitiated after consultation 
with the Medical Monitor  
• Hold study treatment in participants with ACR ≥2 mg/mg (2000 mg/g), perform 
further evaluation for acute glomerulonephritis, as clinically indicated.  If acute 
glomerulonephritis is confirmed or probable (i.e., meets clinical definition of 
rapi[INVESTIGATOR_103020] [RPGN] if biopsy not feasible), 
[COMPANY_004]3228836 should be per manently discontinued  
• Delay in treatment of suspected RPGN should be avoided.  
If any of the following are observed, results should be confirmed , and if confirmed, further 
evaluation for alternative causes should be pursued in consultation with the Medical 
Monitor:  
TMF-11822142  CONFIDENTIAL   
  212602  
49 
 • Persistent ACR 0.03 mg/mg (30 mg/g)  
• Blood in urinalysis 5 RBC per high power field ( HPF) confirmed by [CONTACT_103068]  
• Persistent elevation of serum creatinine (>26.52 mol/L or 0.3 mg/dL change from 
baseline)  
Following confirmation of the criteria above, further evaluation may include but not be 
limited to a [ADDRESS_114025], renal 
ultrasound, urine microscopy, serum urea and creatinine, platelet count, urgent serum 
vasculitis screen [includi ng ANCA, ANA, dsDNA, cryoglobulins], serum protein 
electrophoresis (SPEP)/urine protein electrophoresis (UPEP), and complement panel (C3, 
C4, C5a and Bb).  Further evaluation and actions should be determined by [CONTACT_103069].  
7.1.5.  Study Intervention Restart or Rechallenge after Stoppi[INVESTIGATOR_103021] (i.e., study treatment 
discontinued) by [CONTACT_103070].  
Study intervention res tart may be considered only for liver events as follows:  
Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_103022] a clear u nderlying cause (other than DILI) of the liver event (e.g. biliary obstruction, 
pancreatic events, hypotension, acute viral hepatitis). Furthermore, restart is not permitted 
following liver stoppi[INVESTIGATOR_42257] -related hepat itis. 
• Approval by [CONTACT_103071]:  
o Investigator requests consideration for study intervention restart if liver chemistries 
have a clear underlying cause (e.g., biliary obstruction, hypotension and liver 
chemistrie s have improved to normal or are within 1.5 x baseline and ALT 
<3xULN).  
o Possible study intervention -induced liver injury has been excluded by [CONTACT_103072]. This includes the absence of markers of 
hypersensitivity (otherwise unexplain ed fever, rash, eosinophilia). Where a study 
intervention has a confirmed genetic marker associated with liver injury, the 
presence of the marker should be excluded. If study intervention -related liver injury 
cannot be excluded, the guidance on rechallenge  will apply.  
o There is no evidence of alcohol -related hepatitis.  
o Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) 
approval of study intervention restart has been obtained  (if required) . 
TMF-11822142  CONFIDENTIAL   
  212602  
50 
 If restart of study intervention is approved by [CONTACT_10827] K Medical Governance in writing:  
• The participant must be provided with a clear description of the possible benefits and 
risks of study intervention administration including the possibility of recurrent, more 
severe liver injury or death.  
• The participant must also provide signed informed consent specifically for the restart 
of study intervention. Documentation of informed consent must be recorded in the 
study file.  
• Study intervention must be administered at the dose specified by [CONTACT_23983]  
• Partic ipants approved by [CONTACT_103073] a week for liver function tests until stable liver function tests have been 
demonstrated and then standard laboratory monitoring may resume as per protocol.  
• If the participant meets protocol -defined liver chemistry stoppi[INVESTIGATOR_103023], study intervention should be permanently discontinued.  
• The Medical Monitor and the IRB/IEC must be informed of the outcome for the 
participant following study intervention restart.  
• [COMPANY_004] must be notified of any adverse events.  
For treatment that has been placed on hold, please follow the guidelines above (Section 
7.1.1  to Section 7.1.4 ). 
7.2. Participant Discontinuation/Withdrawal from the Study  
o A participant may withdraw from the study at any time at his/her own request  or 
may be withdrawn at any time at the discretion of the investigator for safety, 
behavioral, compliance or administrative reasons.  
o The investigator may ask participants to withdraw from study treatment but 
continue with visits instead of withdrawing com pletely from the study.  
o At the time of discontinuing from the study, if possible, an early termination visit 
should be conducted, as shown in the SoA  (see Section 1.3). See SoA for data to 
be collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
o The participant will be permanently discontinued both from the study intervention 
and from the study at that time.  
o If the participant withdraws consent for disclosure of future information, the 
sponsor may retain and continue to use any data collected before such a withdrawal 
of consent.  
o If a participant withdraws from the study, he/she may requ est destruction of any 
samples taken and not tested, and the investigator must document this in the site 
study records.  
 
TMF-[ADDRESS_114026] be taken if a participant fails to return to the clinic for a 
required study visit:  
• The site must attempt to contact [CONTACT_103074]/or should continue in the study.  
• Before a participant is deemed lost to follow up, the investigator or desi gnee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 
telephone calls and, if necessary, a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_103075]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix 1 . 
8. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their timing are summarized in the SoA  (see Section 1.3). 
• In selected sites/countries, participants will have the option to use a centralised 
home nursing provider. Only selected visits will have the option to be performed 
as a home visit, these will include drug administration, blood draws, participant 
assessments and data collection. The full specifications of the home nursing 
services will be outlined in the SRM   
• Protocol waivers or exemptions are not allowed  
• Immediate safety concerns should be dis cussed with the sponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention.  
• Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participants screened and to confirm 
eligibility or record reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management 
(e.g., blood count) and obtained before signing of ICF may be utilized for 
TMF-11822142  CONFIDENTIAL   
  212602  
52 
 screening or baseline purposes prov ided the procedure met the protocol -specified 
criteria and was performed within the time frame defined in the SoA.  
• Repeat or unscheduled samples may be taken for safety reasons or for technical 
issues with the samples.  
8.1. Efficacy Assessments  
The primary obje ctive measurement for efficacy in this study is the assessment of 12 
weeks of [COMPANY_004]3228836 treatment on serum HBsAg levels  in participants with CHB.  The 
primary efficacy endpoint is achieving serum HBsAg level <LLOQ by [CONTACT_10585] 12.  
Any HBsAg greater than LLOQ a fter achieving HBsAg seroclearance needs to be 
confirmed by [INVESTIGATOR_1312] -test within [ADDRESS_114027] is not confirmed.  
HBsAg and HBV DNA are collected for primary and secondary efficacy endpoint s as per 
the SoA  (see Section 1.3).  Details of sample collection can be found in the SRM.  
8.2. Safety Assessments  
Planned time points for all safety as sessments are provided in the SoA  (see Section 1.3). 
Additional time points for safety tests (such as vital signs, physical exams and laboratory 
safety tests) may be added during the course of the study based on newly available data to 
ensure appropriate safety monitoring.  
8.2.1.  Physical Examinations  
A complete physical exam will be conducted at the Screening visit.  Symptoms directed  
exams will be conducted at all other time points  (please refer to the SRM  for details) .  
• A complete physical exam will include, at a minimum, assessment of the 
dermatologic, cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and neurological 
systems. Height a nd weight will also be measured and recorded (with participant 
wearing daytime clothing with no shoes).  
• Investigators should pay special attention to clinical signs related to previous 
serious illnesses.  
8.2.2.  Injection Site Reactions  
Injection Site Reactions ( ISRs) are any experiences which occur at the site of injection of 
the study treatment. Participants will be monitored closely for the following in relation to 
ISRs and ISRs should be recorded as AEs:  
• Pain or tenderness  
• Erythema or redness  
• Induration or sw elling  
• Pruritus  
TMF-11822142  CONFIDENTIAL   
  212602  
53 
 Injection site reactions will be graded according to the criteria provided in the Division of 
AIDS (DAIDS) grading table (see Appendix  3). 
8.2.3.  Vital Signs  
Temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed.  
Blood pressure and pulse measurements will be assessed  with a completely automated 
device. Manual tec hniques will be used only if an automated device is not available.  
Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_114028] 
for the participant in a quiet setting without distractions (e.g., television, cell phones).  
Vital signs will be measured after [ADDRESS_114029] nominal time.  
8.2.4.  Electrocardiograms  
The ECG is for screening purposes only.  
Single 12 -lead ECG will be obtained locally as outlined in the SoA (see Section 1.3) using 
an ECG machine that automatically calculates the heart rate and measures PR,  QRS, QT, 
and QTc intervals. Manual calculation, if an automatic calculation is not available, is 
acceptable.  
 
8.2.5.  Clinical Safety Laboratory Assessments  
Refer to Appendix [ADDRESS_114030] of clinical laboratory tests to be performed and to the SoA 
for the timing and frequency  (see Section 1.3).  
The investigat or must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448]'s condition.  
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline 
or are no longer considered significantly abnormal by [CONTACT_103076].  
If such values do not return to normal/baseline within a period of time judged reasonable 
by [CONTACT_093], the etiology should be identified, and the sponsor notified.  
If such values do not return to normal/baseline or are still considered significantly 
abnormal by [CONTACT_103077]’s last visit, additional follow -up should be 
discussed with the sponsor.  
TMF-[ADDRESS_114031] be conducted 
in accordance with the laboratory manual and the SoA.  
8.2.6.  Adverse Events and Serious Adverse Events  
The definitions of a n AE or SAE can be found in Appendix 3 . 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally  authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered rel ated to the study intervention or the study, 
or that caused the participant to discontinue the study intervention (see Section 7).  
[IP_ADDRESS].  Time Period and Frequency for Collecting AE and SAE Information  
All AEs and SAEs will be collected from the signing of the informed consent form until 
the final follow -up visit  at the time points specified in the SoA (Section 1.3).  However, 
AEs and SAEs that occur prior to the first administration of investigational medicinal 
product should be recorded only if assessed as related to study participation (e.g., proto col-
mandated procedures or invasive tests) . 
Medical occurrences that begin before the start of study intervention but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the case report form (CRF) not the AE section.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under 
no circumstance should this exceed 24 hours,  as indicated in Appendix 3 . The investigator 
will submit any updated SAE data to the sponsor within 24  hours of it being available.  
Investigators are not obligated to actively seek AEs or SAEs after the conclusion of the 
study participation. However, if the investigator learns of any SAE, including a death, at 
any time after a participant has been discharged from the study, and he/she considers the 
event to be reasonably related to the study intervention or study participation, the 
investigator must promptly notify the sponsor.  
[IP_ADDRESS].  Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care will be taken not to introduce bias when detecting AE and/or SAE.  Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrence.  
[IP_ADDRESS].  Follow -up of AEs and  SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  will be followed until the event is 
resolved, stabilized, otherwise explained, or the participant is lost to follow -up (as defined 
in Section 7.3). Further information on follow -up procedures is given in Appendix 3 . 
TMF-11822142  CONFIDENTIAL   
  212602  
55 
 [IP_ADDRESS].  Regulatory Reporting Requirements for SAEs  
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of par ticipants and the safety of 
a study intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinic al investigation. 
The sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent 
Ethics Committees (IEC), and investigators.  
For all studies except those utilizing medical devices investigator safety reports must be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regulatory requirements and sponsor policy and forwarded to investigators as necessary.  
An inv estigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the sponsor will review 
and then file it along with the Investigator’s Brochure and will notify the IRB/IEC, if 
appropriate according to local requirements.  
8.2.7.  Pregnancy  
Details of all pregnancies in female participants will be collected after the start of study 
intervention and until no longer than 6 to 8 weeks following the estimated delivery date.  
If a pregnancy is reported, the investigator should inform [COMPANY_004] within 24 hours of  learning 
of the pregnancy and should follow the procedures outlined in Appendix 4 . 
Abnormal  pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE.  
8.2.8.  Cardiovascular and Death Events  
For any cardiovascular events detailed in Appendix 3  and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the CRF will be 
required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non -cardiovascular death.  
The CV CRFs are presented as queries in response to reporting of certain CV medical 
dictionary for regulatory activities (MedDRA) terms.  The CV information should be 
recorded in the specific car diovascular section of the CRF within one week of receipt of a 
CV Event data query prompting its completion.  
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be c ompleted within one week 
of when the death is reported.  
TMF-[ADDRESS_114032]  
[IP_ADDRESS].  ALT Increases  
The liver is a site of accumulation of antisense oligonucleotides and this has been exploited 
in the treatment of liver related diseases.  
Outside the  setting of disease reactivation or rebound viremia, the aetiology of ALT 
increase (flares) in CHB patients is currently uncertain. It has been postulated that ALT 
flares are evidence of reactivation of the immune system in the liver with accompanying 
clearance of infected hepatocytes, particularly when observed during immunotherapy or 
spontaneous loss of HBsAg. Therapeutic ALT flares have been shown to correlate with 
antiviral effect in blood (i.e. declines in HBV DNA, and/or HBsAg).  
A monitoring strategy of ALT is presented in Section 7.1.1 . 
[IP_ADDRESS].  Vascular Inflammation and Complement Activation  
Inflammatory and immune changes are recognized as a class effect of ASOs.  Despi[INVESTIGATOR_103024] -related vascular adverse events in patients, the nature of the toxicity 
demands a conservative approach to care and monitoring to ensure the safety of 
participants.  Because the complement -mediated mechanism of vascular inflamm ation in 
monkeys has been well established, a monitoring strategy has been proposed in patients 
that encompasses a multi -pronged approach for monitoring of this toxicity, from separate 
mechanistic, phenotypic and organ -specific perspectives.  
Vascular infla mmation will be monitored through various inflammatory markers (e.g., 
complement factors, hs -CRP, ANCA, MCP -1) and presence of clinical signs and 
symptoms.  
A monitoring strategy of vasculitis and complement activation is presented in Section 
7.1.2  
[IP_ADDRESS].  Thrombocytopenia  
Thrombocytopenia, decreased platelets, is a well -recognized toxicity associated with ASOs 
and is monitorable in the clinic. Two types of thrombocytopenia have been described by 
[CONTACT_103078] 2 -MOE ASOs.  One type is a rapid onset, unpredictable 
thrombocytopenia that may present with mild or moderate bleeding, however, catastrophic, 
fatal bleeding can occur.  The other more common type  is characterised by a gradual 
decline in platelets leading to mild to severe thrombocytopenia and can be asymptomatic 
or associated with mild to severe bleeding.  
A monitoring strategy of platelet count is presented in Section 7.1.3 . 
[IP_ADDRESS].  Renal Injury  
Glomerulonephritis, including rapi[INVESTIGATOR_103025], has been reported 
with ASOs and is thought to be a result of the proinflammatory effect of ASOs.  
Accumulation of antisense oligonucleotides in proximal tubule cells of the kidney, is 
TMF-11822142  CONFIDENTIAL  
212602  
57 thought to sometimes lead to increased tubular proteinuria (as described in preclinical 
studies).  Increases in urine protein have been described in the clinic.  
A monitoring strategy of renal function (e.g., SCr, ACR) is presented in Section 7.1.4 . 
[IP_ADDRESS].  Injection Site Reactions  
Injection site reactions were the most commonly reported treatment -related adverse event 
in previous studies with [COMPANY_004]3228836. Injection site reactions included, but were not 
limited to, pain, erythema and pruritus. Injection site reactions will be assessed at all dosing 
visits and, if pres ent, should be reported as AEs.  
8.3. Pharmacokinetics  
Blood samples will be collected for measurement of [COMPANY_004]3228836 trough plasma 
concentrations and plasma concentrations during the terminal elimination phase as 
specified in the SoA  (see Section 1.3). 
•Instructions for the collection and handling of biological samples will be provided by
[CONTACT_456]. The actual date and time (24 -hour clock time) of each sam ple will be
recorded.
•PK samples will be used to evaluate the PK of [COMPANY_004]3228836, and explore PK -PD
relationships.
•Samples collected for PK analyses may also be used to evaluate safety or efficacy
aspects related to concerns arising during or after the stud y.
8.4. Biomarkers  
 
 
.  
 
 
  
CCI
CCI
CCI
TMF-[ADDRESS_114033] in pa rticipants receiving 
concomitant NA therapy due to the suppression of HBV viral replication.  Ongoing viral 
replication during [COMPANY_004]3228836 treatment (e.g., due to virological breakthrough) may 
increase the risk of the development of resistance.  Investigato rs should therefore consider 
resistance monitoring for participants who experience virological breakthrough whilst still 
receiving [COMPANY_004]3228836 (i.e., haven’t completed treatment).  
 
 
   
  
HBsAg levels for each participant will be measured throughout the study. In addition to 
the standard HBV DNA virological failure cri teria defined above, HBV resistance 
monitoring will also include analysis of isolates from participants with sub -optimal HBsAg 
levels in the absence of detectable HBV DNA.  
CCI
CCI
TMF-11822142  CONFIDENTIAL   
  212602  
59 
 8.6. Medical Resource Utilization and Health Economics  
Medical Resource Utilization and H ealth Economics parameters are not evaluated in this 
study.  
9. STATISTICAL CONSIDER ATIONS  
9.1. Statistical Hypotheses  
The primary objective of the study is to assess the efficacy of 12 weeks of [COMPANY_004]3228836 
treatment in Hepatitis B e -antigen negative participants on  nucleos(t)ide analogue therapy. 
The primary endpoint is achieving serum HBsAg level <LLOQ by [CONTACT_10585] 12  (at any time 
point up to and includ ing Week 12) without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_103026] . 
An estimation approach with no hypothesis testing will be used to address the primary 
objective. The primary assessment of interest is the point estimate of percent of participants 
achieving serum HBsAg level <LLOQ (without the use of  PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014]) by [CONTACT_10585] 12 with the 95% credible interval . Other 
intercurrent events such as discontinuation of, interruption of, and adherence to IP will be 
ignored (treatment policy). In addition, posterior probabiliti es that the true percent is 
greater than the desired threshold of 50% will be provided using a Bayesian probability 
approach.  
9.2. Sample Size Determination  
Approximately 20 participants will be targeted to assign to treatment.  
Primary Endpoint  
It is assumed t hat the number of participants achieving serum HBsAg level <LLOQ by 
[CONTACT_10585] 12 without the use of PEG -interferon or other immunomodulator therapi[INVESTIGATOR_103027] 
a Binomial distribution, with a weakly informative prior beta (0.5, 0.5) for the true 
response. The pre cision for a range of true response rates with 95% credible intervals are 
shown in Table 9. 
Table 9 95% Credible Interval for Percent  of Participants  achieving HBsAg 
<LLOQ by [CONTACT_10585] 12  
Sample size 
per arm  Number of Participants  
with HBsAg <LLOQ  Percent of Participants  
with HBsAg <LLOQ  95% Credible 
Interval*  
20 8 40% 20% – 61% 
10 50% 29% - 71% 
12 60% 39% - 80% 
14 70% 50% - 87% 
16 80% 61% - 94% 
*95% highest posterior density interval  
TMF-11822142  CONFIDENTIAL   
  212602  
60 
 With 20 participants, if the observed response rate is 60%, 70% and 80%, then the lower 
bound of the 95% credible interval excludes values below 39%, 50% and 61%, 
respectively. The posterior probability th at the percent of participants achieving 
HBsAg<LLOQ by [CONTACT_10585] 12 is greater than 50% will be calculated from the implied Beta 
posterior, given the actual number of responders observed.  
The operating characteristics based on at least 75% posterior confidence that the true 
percentage of participants achieving serum HBsAg level <LLOQ exceeds 50% (desired for 
further mechanistic exploration of the therapeutic effects of [COMPANY_004]3228836 via intrahepatic 
immunophenotypi[INVESTIGATOR_007]) are shown in Table 10, for various assumed sample sizes and true 
response rates. A weakly informative prior beta (0.5, 0.5) is used. With a sample size of [ADDRESS_114034] 12 participant s achieving HBsAg  <LLOQ (observed 
percent of 60%) then the posterior probability that the true percent is greater than 50% will 
be greater than 75%.  
Table 10 Study Operating Characteristics by [CONTACT_103079] N (% ) of 
Participants  
with HBsAg 
<LLOQ 
required for 
meeting 
Criteria    
Probability of Meeting Criteria  
 if True Response Rate =  
30% 40% 50% 60% 65% 70% 75% 
Probability 
(true 
response rate 
>50%)>75%  10 7 (70%)  1% 5% 17% 38% 51% 65% 78% 
15 9 (60%)  2% 10% 30% 61% 75% 87% 94% 
18 11 (61%)  1% 6% 24% 56% 73% 86% 94% 
20 12 (60%)  1% 6% 25% 60% 76% 89% 96% 
24 14 (58%)  0% 5% 27% 65% 82% 93% 98% 
30 17 (57%)  0% 5% 29% 71% 87% 96% 99% 
 * response rate defined as percent of participants  achieving HBsAg<LLOQ by  [CONTACT_10585] 12  
Based on these operating characteristics, for a true response rate of 60%, the proposed 
sample -size of 20 has 60% probability of confirming a true rate of at least 50%, and if the 
true rate is 70%, there is an 89% chance of confirming a true rate greater than 50%.  
Biomarker Endpoints  
Given a sample size of 20, the confidence intervals for the ratio in change from baseline in 
RNAseq (signature) scores between those achieving versus not achieving HBsAg<LLOQ 
are shown below, assuming a range of effect  sizes and between -participant  coefficients of 
variation (CVb).   
Example of one scenario with 60% of the participants achieving HBsAg < LLOQ is given 
below. With relatively smaller between participant  variability  and larger effect size , a 
sample size of 2 0 is appropriate to achieve an acceptable level of precision in detecting the 
differential responses in biomarker outcomes corresponding to HBsAg responses. For 
TMF-11822142  CONFIDENTIAL   
  212602  
61 
 example, in the scenario where 60% of participants achieve HBsAg <LLOQ, if CVb = 0.4 , 
the 95% C I excludes 1 for geometric mean ratios of 0.6 and below, and for 1.7 and above.  
12 Participants  (60%) Achieving HBsAg<LLOQ)  
CVb 95% CI for Ratio of Geometric Mean of Fold Change from Baseline for Participants 
achiev ing vs. not achiev ing HBsAg<LLOQ  
0.6 0.8 1 1.2 1.4 1.7 2.0 
0.2 [0.50, 0.73]  [0.66, 0.97]  [0.83, 1.21]  [0.99, 1.45]  [1.16, 1.69]  [1.41, 2.06]  [1.65, 2.42]  
0.4 [0.41, 0.87]  [0.55, 1.16]  [0.69, 1.45]  [0.83, 1.74]  [0.97, 2.03]  [1.17, 2.46]  [1.38, 2.89]  
0.6 [0.35, 1.02]  [0.47, 1.36]  [0.59, 1.70]  [0.71, 2.04]  [0.82, 2.38]  [1.00, 2.89]  [1.18, 3.40]  
0.8 [0.31, 1.18]  [0.41, 1.57]  [0.51, 1.96]  [0.61, 2.36]  [0.71, 2.75]  [0.87, 3.34]  [1.02, 3.93]  
1 [0.27, 1.33]  [0.36, 1.78]  [0.45, 2.22]  [0.54, 2.67]  [0.63, 3.11]  [0.77, 3.78]  [0.90, 4.44]  
1.5 [0.21, 1.70]  [0.28, 2.27]  [0.35, 2.83]  [0.42, 3.40]  [0.49, 3.97]  [0.60, 4.81]  [0.71, 5.66]  
There are no plans for sample size re -estimation.  In certain cases, including but not limited 
to higher than anticipated drop -out rate, higher  than anticipated rates of efficacy , or large 
variability in ALT flare patterns, the sample size may be increased to no more than 24.  
TMF-11822142  CONFIDENTIAL   
  212602  
62 
 9.3. Analysis Sets  
For the purpose of analysis, the following analysis sets are defined:  
Participant Analysis Set  Description  
Screened  All participants who were screened for eligibility  
Enrolled  All participants who passed screening and entered the study  
Note: screening failures (who never passed screening even if rescreened) and 
participants screened but never enrolled into the  study are excluded from the 
Enrolled population as they did not enter the study  
Intent to Treat (ITT)  All participants who received at least one dose of study treatment  
Safety  All participants who received at least one dose of study treatment  
Pharmacokinetic (PK)  All participants in the Safety population who received an active study treatment 
and had at least 1 non -missing PK assessment (Non -quantifiable [NQ] values 
will be considered as non -missing values)  
Note: PK samples that may be affected  by [CONTACT_103080] (PD)  All participants in the Safety population for whom a Pharmacodynamic sample 
was obtained and analy zed. 
 
Defined Analys is Data 
Sets  Description  
Analysis set for primary 
estimand  All Intent to Treat Participants  including all observations on and off treatment .  
Analysis set for secondary 
estimands  All Intent to Treat Participants  including all observations on and off treatment . 
 
9.4. Statistical Analyses  
The statistical analysis plan will be finalized prior to database release.  This section is a 
summary of the planned statistical analyses of the most important endpoints including 
primary and key secondary endpoints. The statistical analysis plan will include a more 
technical and detailed description of the statistical analyses described in this section.  
9.4.1.  General Considerations  
Unless otherwise specified, baseline will be the last value /assessment before the first dose 
of study treatment (Day  1 pre -dose).  If there are multiple assessments collected at the same 
scheduled time, the average of these assessments will be used as the baseline.  
9.4.2.  Primary Endpoint(s)  
The primary analysis will be conducted once the last participant has completed the 
Week  36 visit (completed 24 -weeks of follow -up period) and database lock has been 
TMF-11822142  CONFIDENTIAL   
  212602  
63 
 achieved.  The primary efficacy endpoint is achieving serum HBsAg level <LLOQ at any 
time point during  12-weeks  (includi ng Week 12)  of [COMPANY_004]3228836 treatment.  
The Primary Estimand  supporting the primary objective of the study is defined as:  
• Population: Participants with CHB  who receive at least 1 dose of IP  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 weeks (also on stable nucleos(t) ide 
therapy)  
• Variable: Achieving serum HBsAg level <LLOQ at any time point up to and 
including Week 12  without the use of PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_014]  
• Population -level summary: Percent of participants that achieve serum HBsAg 
level <LLOQ at any time point up to and including Week 12   
• Intercurrent events: Discontinuation of, interruption of, and adherence to IP will 
be ignored (treatment policy) .  
The primary estimand is the percentage of participants with C HB receiving 300 mg 
[COMPANY_004]3228836 for 12 weeks (with at least one dose of IP)  who achieve serum HBsAg 
level <LLOQ at any time point up to and including Week 12 , without the use of PEG -
interferon or other immunomodulator therapi[INVESTIGATOR_014] , regardless of completing IP, 
interruptions in IP or adherence to IP . If PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_103028] , then the participant’s primary outcome will be treated as a failure.  
9.4.3.  Primary Analyses  
Point estimate of the percentage as well as the 95% credible interval  (Highest Density 
Interval, HDI) of participants achieving serum HBsAg level <LLOQ by [CONTACT_10585] 12 will be 
provided.  
A Bayesian approach will be used to estimate the posterior probability of participants that 
achieve serum HBsAg level <LLOQ by [CONTACT_5875] 12 exceeding  50%.  A weakly informative 
prior beta (0.5, 0.5) will be used.  
Let Y be the number of responders from N participants,  
Y~ Binomial (N, p)  
Where p is virologic response rate.  
The posterior distribution for p is  
P(p|y, N) ~ Beta (y + 0.5, N – y + 0.5)  
The posterior probability that the true rate of participants  achieving LLOQ by [CONTACT_10585] 12 
being greater than 50%  will be calculated from the posterior distribution.  
Additional analyses for the primary endpoint may be included as supportive analyses.  
TMF-11822142  CONFIDENTIAL   
  212602  
64 
 9.4.4.  Secondary En dpoint(s)  
Estimands  supporting the secondary objective of assessing sustainability of serum HBsAg 
loss by [CONTACT_23983]3228836 for up to 24 weeks off -treatment  are defined as follows : 
• The group of estimands supporting this objective in participants with CHB 
receiving 300 mg [COMPANY_004]3228836 for 12 weeks  (with at least one dose of IP ) is the 
percentage of participants for each variable regardless of completing IP, 
interruptions in IP or adherence to IP,  without the use of PEG -interferon or other 
immunomodulator ther api[INVESTIGATOR_014] . If PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_103029]’s outcome will be treated as a failure.  
 
• Variables:  
o Sustained HBsAg Response (HBsAg <LLOQ) for 24 weeks after the 
planned end of [COMPANY_004]3228836 treatment  without the use of PEG -interferon 
or other immunomodulator therapi[INVESTIGATOR_014]  
▪ HBsAg from Week 13 to Week 36 will be used to assess sustained 
HBsAg response after the planned end of [COMPANY_004]3228836 treatment .  
o Sustained HBsAg Response (HBsAg <LLOQ) for 24 weeks after the 
actual  end of G SK3228836 treatment  without the use of PEG -interferon or 
other immunomodulator therapi[INVESTIGATOR_014]  
▪ HBsAg for 24 weeks after end of actual treatment will also be used 
to assess sustained HBsAg response after the actual end of 
[COMPANY_004]3228836 treatment . 
 
• Population Summary:  percentage of participants for each variable.  
 
• Analysis windows for the post [COMPANY_004]3228836 treatment assessments will be 
defined in the analysis plan.  
 
Estimands supporting the secondary objective of assessing sustainability of serum HBsAg 
and HBV DN A (Sustained Virologic Response) loss by [CONTACT_23983]3228836 for up to 24 weeks 
off treatment are defined as follows:  
• The group of estimands supporting this objective in participants with CHB 
receiving 300 mg [COMPANY_004]3228836 for 12 weeks (with at least one dose of IP) is the 
percentage of participants for each variable regardless of completing IP, 
interruptions in IP or adherence to IP, without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014] . If PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_103030]’s outcome will be treated as a failure . 
 
• Variables:  
o Sustained Virologic Response (HBsAg <LLOQ and HBV DNA <LLOQ) 
for 24 weeks after the planned end of [COMPANY_004]3228836 treatment  
TMF-11822142  CONFIDENTIAL   
  212602  
65 
 ▪ HBsAg and HBV DNA from Week 13 to Week 36 will be used to 
assess su stained virologic response after the planned end of 
[COMPANY_004]3228836 treatment  without the use of PEG -interferon or other 
immunomodulator therapi[INVESTIGATOR_014] . 
o Sustained Virologic Response (HBsAg <LLOQ and HBV DNA <LLOQ) 
for 24 weeks after the actual end of [COMPANY_004]3228836 trea tment  
▪ HBsAg and HBV DNA for 24 weeks after end of actual treatment 
will be used to assess sustained virologic response after the actual 
end of [COMPANY_004]3228836 treatment  without the use of PEG -interferon or 
other immunomodulator therapi[INVESTIGATOR_014] . 
 
• Population Summary:  percentage of participants for each variable.  
 
• Analysis windows for the post [COMPANY_004]3228836 treatment assessments will be defined 
in the analysis plan.  
 
Estimands  supporting  the secondary objective of assessing the effect  of 12 weeks 
[COMPANY_004]3228836 on biomarkers an d virus -specific antibody responses are defined as follows:  
- Population : Participants with CHB  who receive at least one dose of IP  
- Treatment : 300  mg [COMPANY_004]3228836 for 12 weeks (also on stable nucleos(t)ide therapy)  
- Intercurrent events : Discontinuation of , interruption of, adherence to IP will be ignored 
(treatment policy) . PEG -interferon or other immunomodulator therapi[INVESTIGATOR_103000] . 
1) Categorical Variables : 
• Achieving HBsAg <LLOQ  over time  
• Achieving HBV DNA <LLOQ over time  
• Achieving HBsAg <LLOQ  and HBV DNA <LLOQ over time  
• Categorical changes from baseline in HBsAg (e.g. <0.5, ≥0.5, ≥1, ≥1.5, ≥3 log 10 
IU/mL) over time  
• ALT>3X ULN over time  
• Categorical changes from baseline in HBe antibody ( anti-HBeAg)   
• Additional categories o f changes from baseline may be added in the RAP.  
 
- Population summary:  Percent  of participants in each category.  
2) Continuous Variables :  
• Actual values and change from baseline over time for HBsAg and HBV DNA   
• HBs antibody (anti -HBsAg) levels  over time  
• Area under the curve (AUC) for ALT  on treatment (12 weeks), during follow up  
(24 weeks), and on treatment + follow up  (36 weeks).  
TMF-11822142  CONFIDENTIAL   
  212602  
66 
  
- Population summary : mean  values and /or mean changes from baseline for each variable  
3) Time to Event Variable  
• Time to Maxi mum ALT (ALT must be greater than  3xULN ) during 36 weeks  
(treatment + follow up ) 
 
- Population summary:  Turnbull  estimate for median Time to Maximum ALT (>3xULN ) 
Missing data for variables in this group of estimands will be ignored, only available data 
will be summarized.  Outcome will be assumed missing (Missing At Random) from the 
timepoint when participants  first receive PEG -interferon or other immunomodulator 
therapi[INVESTIGATOR_014].  
Further details will be provided in the RAP.  
9.4.5.  Safety Endpoints  
All safety analyses will be based on the Safety Population.  
Exposure to study medication, measured by [CONTACT_103081], will be summarized.  
The percent of participants reporting adverse events (AEs) will be ta bulated.  The following 
summaries of AEs will be provided:  
• Incidence and severity of All AEs;  
• Incidence and severity of treatment related AEs;  
• Incidence and severity of AEs leading to withdrawal from study;  
• Incidence of serious AEs (SAEs).  
 
Laboratory data and vital signs (absolute values and change from baseline) will be 
summarized by [CONTACT_765].  In addition, the maximum post -baseline toxicity grade (based on 
DAIDS categories) will be tabulated.  
9.4.6.  Exploratory Endpoint(s)  
CCI
TMF-11822142  CONFIDENTIAL   
  212602  
67 
 9.5. Interim Analysis  
Data will be incorporated into regular safety reviews by [CONTACT_103082] B -Clear study  [[COMPANY_004] Document 
Number 2019N420582_00 , Study 209668 ].  
9.6. Independent Data Monitoring Committee (IDMC)  
An independent data monitoring committee (IDMC) will review ongoing safety data in this 
study as described in Section 9.5.  The IDMC will meet on a regular basis as outlined in 
the charter.  
The first data review meeting will be held approximately [ADDRESS_114035]-dose (data cut at approxim ately [ADDRESS_114036] dose [FPFD]).  
Thereafter, the frequency of scheduled meetings depends on participant  enrolment, 
information accumulated and safety event rates but will occur approximately every 
3 months.    
The IDMC/Review Board  charter will describe the procedures related to IDMC operations 
in greater detail. For details on the IDMC, refer to Section 10.1.5 . 
CCI
TMF-11822142  CONFIDENTIAL   
  212602  
68 
 10. SUPPORTING DOCUMENTA TION AND OPERATIONAL 
CONSIDERATIONS  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from internatio nal guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations  
• The protoco l, protocol amendments, ICF, IB, and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated.  
• Any amendments to the protocol will require IE C/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants.  
• The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequent ly in accordance with the requirements, policies, 
and procedures established by [CONTACT_1201]/EC  
• Notifying the IRB/IEC of SAE or other significant safety findings as 
required by [CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and a dherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable) , European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), 
and all other applicable local reg ulations  
10.1.2.  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to  the appropriate regulatory authorities. 
TMF-11822142  CONFIDENTIAL   
  212602  
69 
 Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
10.1.3.  Informed Consent Process  
o The investigator or his/her repres entative will explain the nature of the study to 
the participant or his/her legally authorized representative and answer all 
questions regarding the study.  
o Participants must be informed that their participation is voluntary. Participants or 
their legally authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_114037] (HIPAA) 
requirements, where applicable, and the IRB/IEC or study center.  
o The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informe d consent 
must also sign the ICF.  
o Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study.  
o A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorized representative.  
A participant who is rescreened is not required to sign another ICF if the rescreening 
occurs within 45 days from the previous ICF signature d ate. 
[COMPANY_004] (alone or working with others) may use participant’s coded study data and samples 
and other information to carry out this study; understand the results of this study; learn 
more about [COMPANY_004]3228836 or about the study disease; publish the results of t hese research 
efforts; work with government agencies or insurers to have [COMPANY_004]3228836  approved for 
medical use or approved for payment coverage.  
The ICF contains a separate section that addresses the use of participant data and 
remaining samples for optiona l further research. The investigator or authorised designee 
will inform each participant of the possibility of further research not related to the 
study/disease. Participants will be told that they are free to refuse to participate and may 
withdraw their c onsent at any time and for any reason during the storage period. A 
separate tick box will be required to document a participant's agreement to allow any 
participant data and/or remaining leftover samples to be used for further research not 
related to the s tudy/disease. Participants who decline further research will tick the 
corresponding “No” box.  
10.1.4.  Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records or datasets that are transferred to the sponsor will con tain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred.  
TMF-11822142  CONFIDENTIAL   
  212602  
70 
 • The participant must be informed that his/her personal study -related data will be 
used by [CONTACT_10999]. The level of 
disclosure must also be explained to the participant who will be required to give 
consent for their data to be used as described in the informed consent.  
• The participant must be informed that his/her medical records  may be examined 
by [CONTACT_103083], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
10.1.5.  Committees Structure  
Independent Data Monitoring Committee : The o verall responsibility of the IDMC, which 
consists of at least [ADDRESS_114038] the ethical and safety 
interests of participants recruited into clinical studies while ensuring the scientific 
validity of the studies. The IDMC wi ll meet at predefined times for each study, as well as 
ad hoc (as deemed appropriate), to evaluate the risk versus benefit of [COMPANY_004]3228836.  
Specific responsibilities of the IDMC include:   
1. Reviewing the IDMC Charter supplied by [CONTACT_103084]; all IDMC members must approve and sign the Charter prior to 
enrolling the first patient into the study . 
2. Determining the type of information needed for review of efficacy/safety data, as 
required, in the context of benefi t/risk.  
3. Recommending the format for the presentation of this information.  
4. Reviewing data collection methods, safety/efficacy monitoring procedures and 
making recommendations for additions or adjustments to the trial design following 
interim analyses (IA).  
[COMPANY_004] is responsible for the selection of IDMC members.  The IDMC Chairperson may 
assist in selecting IDMC members.  The skills and experiences necessary to properly 
fulfil the role of the IDMC ( e.g., relevant medical specialties) require careful 
considerati on and have been pre -specified by [CONTACT_23983].  In the event that a member is unable 
to continue participation on the IDMC, [COMPANY_004], in conjunction with the IDMC Chairperson, 
will recommend a replacement.  [COMPANY_004] has the final decision on the replacement.  No 
substitutio n of members is permissible for individual meetings.  
Internal Safety Review Team (SRT):   A separate internal safety review team will meet to 
review all participants’ safety data on a regular basis.  
10.1.6.  Dissemination of Clinical Study Data  
o Where required by [CONTACT_103085], an investigator signatory 
will be identified for the approval of the clinical study report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportu nity to review the complete study results at a 
[COMPANY_004] site or other mutually -agreeable location.  
TMF-[ADDRESS_114039] in the creation of 
knowledge and understanding . 
10.1.7.  Data Quality Assurance  
o All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically (e. g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate 
and correct by [CONTACT_1189].  
o The investigator must maintain accurate documentation (source data) that 
supports the informati on entered in the CRF.  
o The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents.  
o Monitoring details describing strategy (e.g., risk -based initiativ es in operations 
and quality such as Risk Management and Mitigation Strategies and Analytical 
Risk-Based Monitoring), methods, responsibilities and requirements, including 
handling of noncompliance issues and monitoring techniques (central, remote, or 
on-site monitoring) are provided in the Monitoring Plan.  
o The sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
o The sponsor assumes accountability for actions delegated to other individuals 
(e.g., Contract Research Organizations).  
o Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights o f participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
o Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] 25 years from the issue of the final 
Clinical Study Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No r ecords may be 
destroyed during the retention period without the written approval of the sponsor. 
TMF-11822142  CONFIDENTIAL   
  212602  
72 
 No records may be transferred to another location or party without written 
notification to the sponsor.  
o Quality tolerance limits (QTLs) will be pre -defined in  the trial master file to 
identify systematic issues that can impact participant safety and/or reliability of 
study results. These pre -defined parameters will be monitored during and at the 
end of the study and all deviations from the QTLs and remedial act ions taken 
will be summarized in the clinical study report.  
 
10.1.8.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site . 
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer reco rds, depending on the study. Also, current medical records must be 
available.  
• Definition of what constitutes source data and its origin can be found in the RAP  
• The investigator must maintain accurate documentation (source data) that 
supports the informatio n entered in the CRF.  
• Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected ; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
 
10.1.9.  Study and Site Start and Closure  
The study start date is the date on which the  clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first site open and will be the study start date.  
[COMPANY_004] or its designee reserves the right to close the study site or terminate the study at any 
time for any re ason at the sole discretion of [COMPANY_004]. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator m ay initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
TMF-11822142  CONFIDENTIAL   
  212602  
73 
 Reasons for the early closure of a study site by [CONTACT_103086]:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of furt her study intervention development  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform 
the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reaso n for termination or suspension, as specified 
by [CONTACT_1214]. The Investigator shall promptly inform the 
participant and should assure appropriate participant therapy and/or follow -up. 
10.1.10.  Publication Policy  
• The results of this study  may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary 
information and to provide comments.   
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally 
support publication of multicenter studies only in their entirety and not as 
individual  site data. In this case, a coordinating investigator [INVESTIGATOR_31776].  
• Authorship will be determined by [CONTACT_14346].  
TMF-11822142  CONFIDENTIAL   
  212602  
74 
 10.2.  Appendix 2: Clinica l Laboratory Tests  
The tests detailed in Table 11 will be performed by [CONTACT_2237].  Local laboratory 
samples may still be collected as needed by [CONTACT_779].  
Local laboratory results are required for analysis of platelets during the dosing period and 
be available for the investigator’s review prior to dosing. A sample for central analysis is 
obtained in parallel  
Otherwise, local laboratory results are only requi red in the event that the central laboratory 
results are not available in time for either study intervention administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central analysis 
is obtained in paral lel.  
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.  
Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].  
Pregnancy Testing:  
Refer to Section 5.1 Inclusion Criteria for screening pregnancy criteria.  Additional serum 
or urine pregnancy tests may be performed, as determined necessary by [CONTACT_103087], t o establish the absence of pregnancy at any time during 
the participant's  participation in the study.  
Table 11 Protocol -Required Laboratory  Tests  
Laboratory 
Assessments  Parameters  
Hematology  Platelet Count1  RBC Indices:  
MCV  
MCH  WBC count (with 
Differential if WBC 
abnormal) : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC Count  
Hemoglobin  
Hematocrit  
Clinical 
Chemistry  Blood Urea 
Nitrogen (BUN)  Potassium  Aspartate 
Aminotransferase  
(AST)/  Serum 
Glutamic -
Oxaloacetic 
Transaminase  
(SGOT)  Total, indirect 
and direct 
bilirubin  
 Creatinine  Sodium  Alanine 
Aminotransferase  
 (ALT)/  Serum 
Glutamic -Pyruvic 
Transaminase  
(SGPT)  Total Protein  
TMF-11822142  CONFIDENTIAL   
  212602  
75 
 Laboratory 
Assessments  Parameters  
 Glucose  Calcium  Alkaline 
phosphatase  Albumin  
Routine 
Urinalysis  • By [CONTACT_5230]  
• Microscopic examination (if blood or protein is abnormal)  
Pregnancy 
testing  • Highly sensitive urine or serum human chorionic gonadotropin (hCG) 
pregnancy test (as needed for women of childbearing potential)2 
Other Tests  • Follicle -stimulating hormone and estradiol (as needed only)  
• Serology (HIV antibody, hepatitis C virus antibody, and hepatitis D virus 
antibody)  
• Hepatitis B serology (hepatitis B surface antigen [HBsAg], hepatitis B 
surface antibody [anti -HBsAg],], hepatiti s B e antibody [anti -HBeAg], 
Hepatitis B virus DNA [HBV DNA], Hepatitis B virus RNA [HBV RNA], 
Hepatitis B core related antigen [HBcrAg])  
• Other laboratory: PT, INR, aPTT, Alpha -fetoprotein, ANCA (MPO -ANCA, 
PR3-ANCA), APRI/Fibrosure, Complement factors C3, C4, C5a, and Bb, 
hs-CRP, MCP -1, angiopoetin II, PBMC, soluble protein, PAX Gene  
• Urine ACR  
• Genetic sample  
• Viral Sequencing: HBV Genotype, H BV DNA, HBV RNA  
 
All study -required laboratory assessments will be performed by a central 
laboratory, with the exception:  
• Platelet counts for investigator decisions may be drawn at local laboratory  
• PBMCs may be processed at the local laboratory  as agreed with the 
Sponsor in advance.  
Additional tests 
listed under 
safety follow -up 
processes  Liver Chemistry Stoppi[INVESTIGATOR_2121]3 
• Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if 
unavailable, obtain heterophile antibody or monospot 
testing);  
o Hepatitis E IgM antibody  
o Hepatitis B virus DNA load  
o Hepatitis C virus RNA load  
o Hepatitis D virus antibody  
• PK sample  
• Serum creatine phospho kinase (CPK) and lactate dehydrogenase 
(LDH).  
• Fractionate d bilirubin, Anti -nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal antibodies and 
quantitative total immunoglobulin G (IgG or gamma globulins).  
• Serum acetaminophen a dduct high performance liquid 
chromatography (HPLC) assay  
TMF-11822142  CONFIDENTIAL   
  212602  
76 
 Laboratory 
Assessments  Parameters  
Drug Induced Vascular Inflammation and Complement Stoppi[INVESTIGATOR_2121]  
• CH50  
• Factor B level  
• Factor H level  
• sC5b -9 
Hematological Stoppi[INVESTIGATOR_2121]  
• anti-platelet antibodies  
Drug Induced Kidney Injury Stoppi[INVESTIGATOR_2121]  
• 24-hour urine analysis  
• renal ultrasound  
• urine microscopy  
• serum urea and creatinine  
• platelets  
• urgent serum vasculitis screen [including ANCA, ANA, dsDNA, 
cryoglobulins ] 
•  serum protein electrophoresis (SPEP)/urine protein electrophoresis 
(UPEP)  
• complement panel (C3, C4, C5a and Bb ) 
 
NOTES:  
1. Platelets will require local/central lab collection while participants are on -treatment; local lab will be optional for 
sites during the post -treatment period  
2. Urine testing will be standard for the protocol unless serum testing is required by [CONTACT_18039]/IEC or 
if urine testing is unavailable  
3. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up as sessments after liver stoppi[INVESTIGATOR_103031] 7.1 and Appendix 6 .  All events of ALT 3 × upper limit of normal 
(ULN) and bilirubin 2 × ULN  (>35% direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) 
>1.5, if INR measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis).  
 
TMF-11822142  CONFIDENTIAL   
  212602  
77 
 10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study intervention, whether or not 
considered related to the study intervention.  
NOTE: An AE can therefore be any unfavorable and unintended sign (i ncluding an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a study intervention.  
 
Definition of Unsolicited and Solicited AE  
• An unsolicited adverse event is an adverse event that was not solicited using a 
Participant Diary and that is communicated by a participant who has signed the 
informed consent. Unsolicited AEs include serious and non -serious AEs.  
• Potential unsolicited AEs may be medically attended (i.e., symptoms or illnesses 
requiri ng a hospi[INVESTIGATOR_11956], or emergency room visit, or visit to/by a health care 
provider). The participants will be instructed to contact [CONTACT_103088](s), as well as any events that, though not 
medically atten ded, are of participant concern. Detailed information about reported 
unsolicited AEs will be collected by [CONTACT_103089]’s records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by 
[CONTACT_103090].  
• Solicited AEs are predefined local at the injection site and systemic events for 
which the participant is specifically question ed, and which are noted by [CONTACT_14350].  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not 
related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
TMF-11822142  CONFIDENTIAL   
  212602  
78 
 • New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
• Signs, symptoms,  or the clinical sequelae of a suspected intervention - intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE u nless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of effic acy will be reported as AE or SAE if they fulfill the definition of an AE 
or SAE.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience a dmission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
 
10.3.2.  Definition of SAE  
An SAE is defined as any serious adverse event that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caus ed death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_12994] 
(usually involving at least an overnight stay) at the hospi[INVESTIGATOR_103032]-11822142  CONFIDENTIAL   
  212602  
79 
 for observation and/or treatment that would not have been appropriate in the 
physician’s office or  outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_42244]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred or was necessary, t he AE should be considered 
serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substa ntial disruption of a person’s ability to 
conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor 
medical significance such as uncomplicated headache, nausea, vomiting, 
diarrhea, influenza, and accidental t rauma (e.g. sprained ankle) which may 
interfere with or prevent everyday life functions but do not constitute a 
substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is a suspected transmission of any infectious agent via an authorised medicinal 
product  
g. Other situations:  
• Possible Hy’s Law case: ALT≥3xULN AND total bilirubin ≥2xULN (>35% 
direct bilirubin) or international normalized ratio (INR) >1.[ADDRESS_114040] be reported 
as SAE  
• Medical or scientific judgment should be exercised by [CONTACT_103091]. Th ese events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, 
intensive treatment for allergic bronchospasm, blood dyscrasias,  
convulsions, or development of intervention dependency or intervention 
abuse.  
10.3.3.  Definition of Cardiovascular Events  
Cardiovascular Events (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
TMF-11822142  CONFIDENTIAL   
  212602  
80 
 • Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revascularization  
10.3.4.  Recording and Follow -Up of AE and SAE  
AE and SAE Re cording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF . 
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] required form.  
• There may be instances w hen copi[INVESTIGATOR_31784]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigato r will assess the intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category utiliz ed for 
rating the intensity of an event; and both AE and SAE can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.  
TMF-11822142  CONFIDENTIAL   
  212602  
81 
 Assessme nt of Causality  
The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the t emporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For ea ch AE/SAE, the investigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred, and the investigator has 
minimal information to include in  the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] . 
• The investigator may change his/her opi[INVESTIGATOR_103033] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_31859]/or causality of the AE or SAE as fully as possible. This 
may include additional labora tory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide [COMPANY_004] with a co py of any post -mortem 
findings including histopathology.  
• New or updated information will be recorded in the originally submitted 
documents.  
• The investigator will submit any updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.  
 
The DAIDS Table [ DAIDS , 2017] is used for grading AEs and provided as a guidance 
for patient management for the consideration of the PI.  The DAIDS table will be used t o 
TMF-11822142  CONFIDENTIAL   
  212602  
82 
 grade the severity of an AE that is not specifically identified in the grading table. In 
addition, all deaths related to an AE are to be classified as grade 5.  
The DAIDS Table is available at the following link:  
https://rsc.niaid.nih.gov/clinical -resear ch-sites/grading -severity -adult -pediatric -adverse -
events -corrected -version -two-one  
 
10.3.5.  Reporting of SAE to [COMPANY_004]  
SAE Reporting to [COMPANY_004]  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool. 
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• The investigator or medically -qualified sub -investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to IP/study participation (causality) within 72 hours of 
SAE entr y into the eCRF.  
• After the study is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or rec eives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor by [CONTACT_756].  
• Contacts for SAE rep orting can be found in the SRM . 
 
SAE Reporting to [COMPANY_004] via Paper Data Collection Tool  
• Facsimile transmission of the SAE paper data collection tool is the preferred 
method to transmit this information to the medical monitor . 
• In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by 
[CONTACT_22855].  
• Initial notification via telephone does not replace the need for the investigator to 
complete  and sign the SAE data collection tool within the designated reporting time 
frames.  
• Contacts for SAE reporting can be found in the study reference manual.  
 
TMF-11822142  CONFIDENTIAL   
  212602  
83 
 10.4.  Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions:  
Woman of Childbearing Potential (WOCBP ) 
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time of menarche until becoming post -menopausal unless permanently 
sterile (see below)  
Notes:  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
o A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the  
absence of [ADDRESS_114041] 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment.  
• Permanent sterilization methods (for the purpose of this study) include:  
o Documented hysterectomy  
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator 
discre tion should be applied to determining study entry.  
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation should 
be considered.  
TMF-11822142  CONFIDENTIAL   
  212602  
84 
 10.4.2.  Contraception Guidance:  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year 
when used consistently and correctly.  
Implantable progestogen -only hormone contraception associated with inhibition of ovulationb 
Intrauterine device (IUD)  
Intrauterine hormone -releasing system  (IUS) b 
Bilateral tubal occlusion  
Vasectomized partner  
Note: Vasectomized partner is a highly effective contraceptive method provided that 
the partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been co nfirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.  
Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when 
used consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc 
oral 
intravaginal  
transdermal  
injectable  
Progestogen -only hormone contraception associated with inhibition of ovulationc 
oral 
injectable  
Sexua l abstinence  
Note: Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
ACCEPTABLE METHODSd 
Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary mode of action  
Male or fema le condom with or without spermicidee 
Cervical cap, diaphragm, or sponge with spermicide  
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods)c 
a. Contraceptive use by [CONTACT_103092].  
TMF-11822142  CONFIDENTIAL   
  212602  
85 
 b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_56801].  
c. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.  
d. Considered effective, but not highly ef fective - failure rate of ≥1% per year.  Periodic abstinence 
(calendar, sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception.  
e. Male condom and female condom should not be used together (due to risk of failure with friction).  
 
10.4.3.  Collection of Pregnancy Information:  
 
Female Participants who become pregnant  
Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study.  
The initial information will be recorded on the appropriate form and submitted to [COMPANY_004]  
within 24 hours of learning of a parti cipant's pregnancy.  
Participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004]  Generally, follow -up will not be required for longer  than 6 to 8 
weeks beyond the estimated delivery date.   
Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.  
While pregnancy itself is not considered to be an AE or SAE,  any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth 
(occurring at >22 weeks gestational age) is always cons idered to be an SAE and will 
be reported as such.  
Any SAE occurring as a result of a post -study pregnancy which is considered 
reasonably related to the study intervention by [CONTACT_093], will be reported to [COMPANY_004]  
as described in Appendix 3 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
Any female participant who becomes pregnant while participating will discontinue study 
intervention or be withdrawn from the study  
 
TMF-11822142  CONFIDENTIAL   
  212602  
86 
 10.5.  Appendix 5: Genetics  
USE/ANALYSIS OF DNA  
• Genetic variation may impact a participant’s response to study intervention, 
susceptibi lity, severity and progression of disease. Variable response to study 
intervention may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis  
• DNA samples will be used for research related to [COMPANY_004]3228836 or CHB and 
related diseases. They may also be used to develop tests/assays including 
diagnostic tests related to [COMPANY_004]3228836 or other 2’ -MOE ASOs, and CHB. 
Genetic research may consist of the analysis of one or more candidate genes or 
the analysis of genetic markers throughout the genome or analysis of the ent ire 
genome (as appropriate)  
• Additional analyses of DNA samples may be conducted if it is hypothesized that 
this may help further understand the clinical data.  
• The samples may be analyzed as part of a multi -study assessment of genetic 
factors involved in t he response to [COMPANY_004]3228836 or study interventions of this 
class. The results of genetic analyses may be reported in the clinical study report 
or in a separate study summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate 
meas ures to protect confidentiality.  
• The samples will be retained while research on [COMPANY_004]3228836 (or study 
interventions of this class) or CHB continues but no longer than [ADDRESS_114042] visit or other period as per local requirements.  
TMF-11822142  CONFIDENTIAL   
  212602  
87 
 10.6.  Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Restart Guidelines  
Phase [ADDRESS_114043] been 
designed to assure participant safety and evaluate liver event etiology.  
The procedures listed below are to be followed if a participant meets any of the liver 
chemistry stoppi[INVESTIGATOR_103034]  7.1.1 . 
If criteria for permanent discontinuation of IP are met, immediately withdraw the 
participant from study treatment.  
Notify the Medical Monitor within 24  hours of learning of the abnormality to confirm 
the participant’s study treatment cessation and follow -up. 
Complete the Liver Event CRF.  
Complete the “Safety Follow -up Procedures” listed below.  
Safety Follow -up Procedures for Participants Who Meet Any of The 
Stoppi[INVESTIGATOR_2121]:  
Viral hepatitis se rology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  
o Hepatitis E IgM antibody.  
o Hepatitis C virus RNA load  
o Hepatitis D virus antibody  
• Obtain a blood sample for pharmacokinetic (PK) analysis as soon as possible 
following the occurrence of an event. Record the date/time of the PK blood sample 
collection and the date/time of the last dose of study treatment prior to blood s ample 
collection on the CRF. If the date or time of the last dose is unclear, provide the 
participant’s best approximation. Instructions for sample handling and shippi[INVESTIGATOR_103014] (SRM).  
• Serum creatine phosphokinase (CPK) a nd lactate dehydrogenase (LDH).  
• Review fractionated bilirubin  
• Assess eosinophilia  
• Record the appearance or worsening of clinical symptoms of hepatitis 
(fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash 
or eosinophilia) as rele vant on the Adverse Event (AE) CRF.  
• Record use of concomitant medications, acetaminophen, herbal remedies, 
other over the counter medications, or putative hepatotoxins on the 
Concomitant Medications CRF.  
TMF-11822142  CONFIDENTIAL   
  212602  
88 
 • Record alcohol use on the Liver Events CRF.  
The foll owing are required for participants who meet the ALT and bilirubin 
stoppi[INVESTIGATOR_103035] . 
• Anti-nuclear antibody, anti -smooth muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies and quantitative total immunoglobulin G (IgG or 
gamma globulins).  
• Serum acetaminophen adduct high performance liquid chromatography 
(HPLC) assay (quantifies potential acetaminophen contribution to liver injury 
in participants with definite or likely acetaminophen use in the preceding 
week [ James , 2009]).  
• Liver imaging (ultrasound, magnetic resonance, or computerized tomography) 
or Liver biopsy to evaluate liver disease.  
o The Li ver Imaging and/or Liver Biopsy CRFs are also to be completed if these 
tests are performed.  
Study intervention rechallenge after stoppi[INVESTIGATOR_23893] (i.e., study treatment 
discontinued) by [CONTACT_103070].  
Study interven tion restart may be considered only for liver events as follows:  
Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_103022] a clear underlying cause (other than drug -induced liver injury [DILI]) of the liver event 
(e.g. biliary obstruction, pancreatic events, hypotension, acute viral hepatitis). 
Furthermore, restart is not permitted following liver stoppi[INVESTIGATOR_103036] -related hepatitis.  
• Approval by [CONTACT_103071]:  
o Investigator requests consideration for study intervention restart if liver chemistries 
have a clear underlying cause (e.g., biliary obstructi on, hypotension and liver 
chemistries have improved to normal or are within 1.5 x baseline and ALT 
<3xULN).  
o Possible study intervention -induced liver injury has been excluded by [CONTACT_103072]. This includes the absence of markers of 
hypersensitivity (otherwise unexplained fever, rash, eosinophilia). Where a study 
intervention has a confirmed genetic marker associated with liver injury, the 
presence of the marker should be excluded. If study intervention -related liver injury 
cannot be e xcluded, the guidance on rechallenge will apply.  
o There is no evidence of alcohol -related hepatitis.  
o Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) 
approval of study intervention restart has been obtained  (if required) . 
TMF-11822142  CONFIDENTIAL   
  212602  
89 
 If restart of study intervention is approved by [CONTACT_90652]:  
• The participant must be provided with a clear description of the possible benefits and 
risks of study intervention administration including the possibility of recurrent, more 
severe liver injury or death.  
• The participant must also provide signed informed consent specifically for the restart 
of study intervention. Documentation of informed consent must be recorded in the 
study file.  
• Study intervention must be administered at the dose specified by [CONTACT_23983]  
• Participants approved by [CONTACT_103093] a week for liver function tests until stable liver function tests have been 
demonstrated and then standard laboratory monitoring may resume as per protocol.  
• If the participant meets protocol -defined liver chemistry stoppi[INVESTIGATOR_103023], study intervention should be permanently discontinued.  
• The Medical Monitor and the IRB/IEC must be informed of the outcome for the 
participant following study intervention restart.  
• [COMPANY_004] must be notified of  any adverse events.  
 
TMF-11822142  CONFIDENTIAL   
  212602  
90 
 10.7.  Appendix  7: Abbreviations and Trademarks  
ACR  albumin to creatinine ratio  
AE adverse event  
ALK alkaline phosphatase  
ALT alanine aminotransferase  
ANC  absolute neutrophil count  
ANCA  Anti-neutrophil cytoplasmic antibody  
APRI  aspartate aminotransferase -platelet index  
aPTT  activated partial thromboplastin time  
ASGPR  asialoglycoprotein receptor  
ASO  antisense oligonucleotide  
AST aspartate aminotransferase  
AUC  area under the concentration -time curve  
AUC (0-24) area under the concentration -time curve from time zero (pre -dose) to [ADDRESS_114044] -dose  
AUC (0-) area under the concentration -time curve from time zero (pre -dose) 
extrapolated to infinite time  
BLRM  Bayesian logistic regression model  
BMI body mass index  
BMD  bone miner al density  
BUN  blood urea nitrogen  
CHB  chronic hepatitis B  
CL/F  apparent subcutaneous plasma clearance  
CKD -EPI [INVESTIGATOR_103037]-induced liver injury  
dL deciliters  
DMPK  drug metabolism and pharmacokinetics  
DNA  deoxyribonucleic acid  
EC 90 concentration that produces 90% of maximal effect  
EC 99 concentration that produces 99% of maximal effect  
ECG  electrocardiogram  
EPIP  Electronic Protocol Inquiry Platform  
ET early termination  
FNA fine needle aspi[INVESTIGATOR_103038], first dose  
FSH follicle stimulating hormone  
GalNAc  N-acetyl galactosamine  
GCP  Good Clinical Practice  
GCSP  Global Clinical Safety and Pharmacovigilance  
GFR  glomerular filtration rate  
[COMPANY_004]  GlaxoSmithKline  
H hours  
HBcrAg  hepatitis B core -related antigen  
HBeAg  hepatitis B virus e -antigen  
Anti- HBsAg  hepatitis B virus surface antibody  
HBsAg  hepatitis B virus surface antigen  
TMF-11822142  CONFIDENTIAL   
  212602  
91 
 HBV hepatitis B virus  
HCC  hepatocellular carcinoma  
hCG human chorionic gonadotropin  
HCV  hepatitis C virus  
HDV  hepatitis D virus  
HIV human immunodeficiency virus  
HPF high-power field  
hs-CRP  high sensitivity C -reactive protein  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
IDO indoleamine 2,[ADDRESS_114045] lower limit of normal  
LLOQ  lower limit of quantification  
m2 square meters  
MCMC  Markov Chain Monte Carlo  
MCP  monocyte chemoattractant protein  
MedDRA  Medical Dictionary for Regulatory Activities  
mEq milliequivalents  
Mg milligrams  
MHRA  Medicines and Healthcare products Regulatory Agency  
Min minutes  
mL milliliters  
mm3 cubic millimeters  
MOE  methoxyethyl  
Msec  milliseconds  
MSDS  Material Safety Data Sheet  
NA nucleos(t)ide analog  
NCA  non-compartmental analysis  
Ng nanograms  
NOAEL  no observed adverse effect level  
Nucleos(t)ide  nucleoside or nucleotide  
PBMC  peripheral blood mononuclear cells  
PD pharmacodynamics(s)  
PEG  pegylated  
PK pharmacokinetic(s)  
PT prothrombin time  
QTcF  Fridericia’s QT correction formula  
RAP Reporting and Analysis Plan  
RBC  red blood cell  
RNA  ribonucleic acid  
RR response rate  
RR ACT response rate in the active group  
RR PBO Response rate in the placebo group  
SAD single ascending dose  
TMF-11822142  CONFIDENTIAL   
  212602  
92 
 SAE serious adverse event  
SC subcutaneous(ly)  
siRNA  small interfering ribonucleic acid  
SoA schedule of activities  
SOP  standard operating procedure  
SPEP  serum protein electrophoresis  
SRM  Study Reference Manual  
SRT Safety Review Team  
t½ terminal half -life 
TCM  traditional Chinese medicine  
tmax time of maximum observed concentration  
U units  
UA urinalysis  
g micrograms  
ULN upper limit of normal  
UPEP  urine protein electrophoresis  
mol micromole  
WBC  white blood cell  
WOCBP  women of childbearing potential  
 
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by [CONTACT_103094]-11822142  CONFIDENTIAL   
  212602  
93 
 11. REFERENCES  
Baraclude (Entecavir) [package insert]. Bristol -Myers Squibb Company. Princeton (NJ); 
2015.  
Bennett  CF and Swayze EE. RNA targeting therapeutics: molecular mechanisms of 
antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 
50: 259 -293.  
Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B  virus 
infections: towards restoration of immune control of viral infection. Postgrad Med J  
2013;89:294 -304. 
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care 
of patients with liver disease during the COVID -19 pandemic: EAS L-ESCMID position 
paper. JHEP Rep. 2020;2(3):100113.   
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. 
Characterization of hepatitis B virus (HBV) -specific T -cell dysfunction in chronic HBV 
infection. J Virol  2007;81:4215 -25. 
Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored 
function of HBV -specific T cells after long -term effective therapy with nucleos(t)ide 
analogues. Gastroenterology  2012;143:963 -73. 
Bristol -Myers Squibb  Company. Baraclude p rescribing information ([LOCATION_003]). 12/[ADDRESS_114046] HBsAg 
seroclearance in patients with inactive chronic hepatitis B virus infection. Clin 
Gastroenterol Hepatol 2012; 10: 297 -302. 
Chi X, G atti P, Papoian T. Safety of antisense oligonucleotide and siRNA -based 
therapeutics, Drug Discovery Today,(2017)  22 (5): 823 -833, ISSN 1359 -6446, 
https://doi.org/10.1016/j.drudis.2017.01.[ADDRESS_114047] J. Abstr. 44th Intersci. C onf. Antimicrob. Agents 
Chemother., abstr. A448, 2004.  
Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its 
role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides 
Nucleic Acids 2001; 20: [ADDRESS_114048], Baker BF, Wiztum JL, Kwoh TJ, Pham NC, Salgado et al.  The effects of 2’ -
O-Methoxyethyl containgin antisense oligonucleotides on platelets in human clinical 
trials.  Nucleic Acid Ther 2017; 27(3):121 -129. 
Division of AIDS. Division of AIDS  (DAIDS) Table for Grading the Severity of Adult 
and Pediatric Adverse Events Version 2.1. National Institutes of Health; Institute of 
TMF-11822142  CONFIDENTIAL   
  212602  
94 
 Allergy and Infectious Diseases, Bethesda, MD; 2017. Available at: http://rsc.tech -
res.com/Document/safetyandpharmacovigi lance/DAIDS_AE_Grading_Table_v2.1_NOV
2017.pdf  
Epi[INVESTIGATOR_54736] (Lamivudine) [package insert]. GlaxoSmithKline. Research Triangle Park (NC); 
2002.  
European Association for the Study of the Liver (EASL ). 2017 Clinical Practice 
Guidelines on the management of hepatitis B virus infection. Electronic address: 
[EMAIL_2023] ; J Hepatol . 2017 Aug;67(2):370 -398. doi: 
10.1016/j.jhep.2017.03.021.  
European Association for the Study of the Liver (EASL).  EASL clinical practice 
guidelines: Management of chronic hepatitis B virus infection. J Hepatol 
2012;57:167 -85. 
Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. 
Hepatology  2009;49([ADDRESS_114049]):S96 -S102.  
Fix OK, Hameed B, Fontana RJ , Kwok RM, McGuire BM, Mulligan DC, et al. Clinical 
Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID -
19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287 -
304. 
Geary RS, Yu RZ, Siwkowski A, Levin  AA. Pharmacokinetic/pharmacodynamics 
properties of phosphorothioate 2ʹ -O-(2-methoxyethyl) -modified antisense 
oligonucleotides in animals and man. In Crooke ST, editor. Antisense Drug Technology: 
Principles, Strategies and Applications, 2nd Edition. Boca R aton, FL. Taylor & Francis 
Group 2008; 305 -326.  
[COMPANY_009] Sciences Inc. Viread prescribing information ([LOCATION_003]). 12/2018 revision.  
Gill US, Pallett LJ, Thomas N, Burton AR, Patel AA, Yona S, Kennedy PTF, Maini MK.  
Fine needle aspi[INVESTIGATOR_103039] i ntrahepatic immunity.  Gut. 2019 
Aug;68(8):1493 -1503. doi: 10.1136/gutjnl -[ADDRESS_114050] of 
antiviral therapy nucleot(s)ide analogues (NUCs).Liver Int. 2017 Jan;[ADDRESS_114051] 1:45 -51. 
doi: 10.1111/liv.[ZIP_CODE]  
[COMPANY_004] Document Number 2019N403517_00.  A Double -Blind, Placebo -Controlled Study 
to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single 
Ascending Dose and Multiple Doses of [COMPANY_004]3389404 in Chronic Hepatitis B  Subjects: 
Part 2, Day 85.  Oct 2019.  
[COMPANY_004] Document Number 2019N420582_00 .  Phase IIb Multi -Center, Randomised, 
Partial -Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with 
[COMPANY_004]3228836 in Participants with Chronic Hepatitis B Virus  (B-Clear) . April 2020.  
TMF-11822142  CONFIDENTIAL   
  212602  
95 
 [COMPANY_004] Document Number 2019N425040_00.  [COMPANY_004]3228836 Investigator’s Brochure. 
Version 1. Feb 2020.  
[COMPANY_004] Document Number 2020N429086_00. ISIS 505358 -CS3 Study Report. Clinical 
Study Report:  A Phase 2, Double -Blinded, Randomized, Placebo -Controlled, Dose -
Escalation Study to Examine the Safety, Tolerability, Pharmacokinetics and Antiviral 
Activity of ISIS [ADDRESS_114052] ewart F, Kowal D, et al. Contraceptive 
Technology. 20th ed. Atlanta, Georgia: Ardent Media Inc; 2011.  
Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified 
oligonucleotides exhibit decreased immune stimulation in mice. J Phar macol Exp Ther  
2000;292:468 -79. 
Henry SP, Kim TW, Kramer -Strickland K, Zanardi TA, Fey RA, Levin AA. Antisense 
Drug Technology: Principles, Strategies and Applications; Toxicologic properties of 2' -
O-methoxyethyl chimeric antisense inhibitors in animals an d man. Crooke ST editor. 2nd 
ed. Boca Raton, [LOCATION_012]:Taylor & Francis Group; 2008.  
Hepsera (Adefovir dipi[INVESTIGATOR_96471]) [package insert]. [COMPANY_009] Sciences, Inc. Foster City (CA); 
2012.  
Höner Zu Siederdissen C, Cornberg M. The role of HBsAg levels in the current 
management of chronic HBV infection. Ann Gastroenterol 2014;27(2):[ADDRESS_114053] in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug  Metab Dispos  2009;37:1779 -84. 
Jaroszewicz J, Ho H, Markova A, Deterding K, Schlue K, Raupach R, et al. Hepatitis B 
surface antigen (HBsAg) decrease and serum interferon -inducible protein -10 levels as 
predictive markers for HBsAg loss during treatment with  nucleoside/nucleotide 
analogues. Antivir Ther 2011; 16(6): 915 -924. 
Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and 
pharmacokinetics. Clin Pharmacokinet 2004;439:595‐612  
Kim GA, Lee HC, Kim MJ, et al. (2014) Incidence of hepatocellular carcinoma after 
HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance.  J Hepatol , 
Vol 62, Issue 5, 1092 –1099.  https://doi.org/10.1016/j.jhep.2014.11.[ADDRESS_114054] a Functional Cure for Hepatitis B Virus Infection. 
Gastroenterol Hepatol (N Y) . 2018;14(7):439‐442.  
Kwoh TJ. Antisense Drug Technology: Principles, Strategies and Applications. An 
overview of the clinical safety experience of first - and se cond -generation antisense 
oligonucleotides. 2 ed. Boca Raton, [LOCATION_012], [LOCATION_002]:Taylor & Francis Group; 2008.  
TMF-[ADDRESS_114055];218: 
1075 -1084. doi: 10.1093/infdis/jiy272.  
Levin AA, Henry  SP, Monteith D, Templin MV. Antisense Drug Technology Principles, 
Strategies, and Applications. Toxicity of antisense oligonucleotides. Crooke ST ed. New 
York:Marcel Dekker; 2001  
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian  
Lamivudine Multicenter Study Group. Lamivudine for patients with chronic hepatitis B 
and advanced liver disease. N Engl J Med  2004;351:1521 -31. 
Liu YY, Liang XS.  Progression and status of antiviral monitoring in patients with 
chronic hepatitis B: from HB sAg to HBV RNA.  World J Hepatol. 2018 Sep;10(9): 603 -
611. doi:10.4254/wjh.v10.i9.603  
Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to 
regulatory approval. Hepatol.  [ADDRESS_114056];66(4):1296 -1313. doi: 10.1002/hep.[ZIP_CODE]. Epub 
2017 Aug 1.  
Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. AASLD practice guidelines. 
Hepatol  2009;50:[ADDRESS_114057]  1993; 91:[ADDRESS_114058], Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can 
modulate the immune response to the nucleocapsid: a mechanism for persistence. J 
Immunol  1998 ;160:2013 -21. 
Minuesa G, Volk C, Molina -Arcas M, Gorboulev V, Erkizia I, Arndt P, et al. Transport 
of lamivudine [( -)-beta-L-2’,3’ -dideoxy -3’-thiacytidine] and high -affinity interaction of 
nucleoside reverse transcriptase inhibitors with human organic cati on transporters 1, 2, 
and 3. J Pharmacol Exp Ther 2009;329:252 –61. 
Op den Brouw M L, Binda RS, van Roosmalen MH, Protzer U, Janssen HLA, van de 
Molen RG, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell 
function: a possible immune es cape mechanism of hepatitis B virus. Immunol  
2009;126:280 -89. 
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al.  Asian -Pacific clinical 
practice guidelines on the management of hepatitis B: a 2015 update.  Hepatol Int. 2016. 
Jan;10(1):1 -98. doi:  10.1007/s12072 -015-[ADDRESS_114059] G, Jaudon MC, et al. Tubular transporters 
and clearance of adefovir. Eur J Pharmacol 2006;540:168 -74. 
Shemesh CS, Yu RZ, Warren MS, et al. Assessment of the drug interaction potential of 
unconjugated and galNAc3 -conjugated 2′ -MOE ASOs. Mol Therapy: Nuc Acids 2017; 9: 
34-47. 
TMF-11822142  CONFIDENTIAL   
  212602  
97 
 Sprengers D, van der Molen RG, Kusters JG, Kwekkeboom J, van der Laan LJW, 
Niesters HGM, et al.  Flow cytometry of fine -needle -aspi[INVESTIGATOR_103040]: A new method 
to monitor the intrahepatic immunological environment in chronic viral hepatitis.  J Viral 
Hepat. 2005 Sep;12(5):  507 -512. doi: 10.1111/j.1365 -2893.2005.[ZIP_CODE].x.  
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwany JP, Jonas MM, et al. Update 
on prevention, dia gnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B 
guidance.  Hepatol. 2018 Apr;67(4): 1560 -1599. doi: 10.1002/hep.[ZIP_CODE].  
Tjwa ETTL, Zoutendijk R, van Oord GW, Boeijen LL, Reijnders JGP, van Campenhout 
MJH, et al. Similar frequencies, phe notype and activation status of intrahepatic NK cells 
in chronic HBV patients after long -term treatment with tenofovir disoproxil fumarate 
(TDF). Antiviral Res. 2016;132: 70 -75. https://doi.org/10.1016/j.antiviral.2016.05.016.  
Tyzeka (Telbivudine) [package  insert]. [COMPANY_001] Pharmaceuticals Corporation. East 
Hanover (NJ); 2013.  
Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by 
[CONTACT_103095]22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007; 24: 811 -815. 
Vanlandschoot P,  Leroux -Roels G. Viral apoptotic mimicry: an immune evasion strategy 
developed by [CONTACT_91292] B virus? Trends  Immunol  2003;24:144 -47. 
Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux -Roels G. Hepatitis B 
virus surface antigen suppresses the  activation of monocytes through interaction with a 
serum protein and a monocyte -specific receptor. J Gen Virol  2002;83:1281 -89. 
Walsh R, Locarnini S. Hepatitis B precore protein: pathogenic potential and therapeutic 
promise. Yonsei Med J  2012;53:875 -85. 
World Health Organization (WHO). Guidelines for the prevention, care and treatment of 
persons with chronic hepatitis B infection. March 2015.  
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R et al. Hepatitis B virus suppresses 
toll-like receptor -mediate d innate immune responses in murine parenchymal and 
nonparenchymal liver cells. Hepatology  2009;49:1132 -40. 
Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline 
during 3 years of telbivudine treatment in hepatitis B e antigen -positive patients. Hepatol 
2010; 52(5): 1611 -1620.  
Xu Q, Wang C, Meng Q, et al. OAT1 and OAT3: targets of drug -drug interaction 
between entecavir and JBP485. Eur J Pharm Sci 2013; 48: 650 -657.  
Yanxiao C, Ruijuan X, Jin Y, Lei C, Qian W, Xuefen Y, et al. Organic anion and cation 
transporters are possibly involved in renal excretion of entecavir in rats. Life Sci 
2011;89:1 –6. 
TMF-11822142  CONFIDENTIAL   
  212602  
98 
 Yip VSK, Cheung TT, Poon RTP, et al. (2016). Does hepatitis B seroconversion affect 
survival outcome in patients with hepatitis B rel ated hepatocellular carcinoma?  Transl 
Gastroenterol  Hepatol ; 1:51  
Yu RZ, Warren MS, Watanabe T, et al. Lack of interactions between an antisense 
oligonucleotide with 2' -O-(2- methoxyethyl) modifications and major drug transporters. 
Nucleic Acid Ther 2016; 26: 111 -117.  
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, et al.  Phase 2a, Randomized, 
Double -blind, Placebo -controlled Study of an Antisense Inhibitor (ISIS 505358) in 
Treatment -naïve Chronic Hepatitis B (CHB) Patients: Safety and Antiviral Efficacy.  
AASLD 2019 Nov 8 -11 [LOCATION_011] . 